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The role of estrogens extends far beyond that of sexual development in 
females. Results from population-based studies indicate that estrogenic factors 
such as reproductive factors and levels of estrogens have a role to play in 
diseases such as hip fracture, breast cancer and lung cancer in postmenopausal 
women. However studies investigating the role of serum estrogenic 
biomarkers in relation to the risk of these diseases are lacking, especially in 
Asians who have different risk profiles compared to Caucasians, such as lower 
serum estrogen levels, lower body mass index and higher consumption of soy 
which is known to be rich in phytoestrogens. 
Using serum obtained from the Singapore Chinese Health Study 
Cohort in Singapore, we investigated the role of estrogenic biomarkers in 
association with risk of hip fracture and breast cancer in postmenopausal 
women. Estrogenic biomarkers were measured with two well validated 
methods. The first method measured the total levels of estrogens (estrone and 
estradiol) and phytoestrogens (genistein and daidzein) using liquid 
chromatography tandem mass spectrometry. In addition, sex hormone binding 
globulin level were measured and free estradiol levels were calculated. The 
second method determined the transcriptional estrogenic activity of estrogen 
receptor (ER) α and/ or ERβ of the serum using a human cell-based assay.  
 Our results showed that higher free estradiol levels and ERα mediated 
bioactivity were independently associated with reduced risk of hip fracture. In 
terms of breast cancer, higher ERα mediated bioactivity was shown to be 
associated with increased risk of breast cancer independent of estrone levels. 
v	  
Lastly, we also looked at the ability of these estrogenic biomarkers to predict 
survival in a hospital-based case control study of postmenopausal lung cancer 
women. Only higher ERβ mediated bioactivity predicted worst survival of 
lung cancer in women. 
These studies show that the measurement of estrogen levels and/or ER 
mediated bioactivity in the serum of postmenopausal women have the 
potential to improve survival prediction, disease risk profiling and provide 
insights on the mechanisms of cancer initiation and progression. Furthermore, 
our findings suggest that compound(s) other than endogenous estrogens may 
exert estrogenic activity and its cumulative effects can be measured through 
ER mediated bioactivity. Further studies to identify these compounds or 
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CHAPTER 1: INTRODUCTION 
1.1 Estrogens  
 Estrogens are steroidal hormones that act most importantly on the 
female reproductive system, but they also act on other organ systems such as 
cardiovascular, skeletal, immune, gastrointestinal and neural sites (Deroo and 
Korach 2006). These hormones are present in both men and women but they 
are usually present at significantly higher levels in women of reproductive age 
where they are involved in the development of female secondary sex 
characteristics, thickening of the endometrium and regulating the menstrual 
cycle (Deroo and Korach 2006).  
 There are three main forms of estrogens, Estrone (E1), Estradiol (E2) 
and Estriol (E3). E3 is only produced during pregnancy in the placenta. The 
primary molecule that begins the synthesis of estrogen is cholesterol. It forms 
androstenodione. Androstenedione is a substance of moderate androgenic 
activity. This compound crosses the basal membrane into the surrounding 
granulosa cells, where it is converted to estrone or estradiol, either 
immediately or through testosterone. This conversion of testosterone to 
estradiol, and of androstenedione to estrone, is catalyzed by the enzyme 
aromatase. The interconversion of estrone to estradiol is further catalyzed by 
enzyme 17-beta hydroxysteroid dehydrogenase. In pre-menopausal women, 
E1 and E2 are produced at higher levels. Upon reaching menopause, the 
ovaries decrease in size and production of E2 decrease dramatically. As the 
major site of E2 production stopped functioning, the level of E2 decline 
considerably compared to E1 levels. The levels of estrogens, particularly E1 in 
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post-menopausal women are maintained by other secondary sources which 
would continue production; mainly in peripheral organs such as adrenal glands, 
fat cells, muscle cells, arterial walls, liver, breasts and brain via conversion of 
androgens by enzyme aromatase independent of E2 levels (Nelson and Bulun 
2001).   
 Natural estrogens function as signaling molecules and exert their 
effects by traveling through the bloodstream and interacting with cells in a 
variety of target tissues. About 98-99% of E2 in the blood is bound to SHBG 
and albumin, and only about 1-2% is freely accessible to target tissues and 
cells (Sodergard, et al. 1982a). 
In this thesis, I focus on the measurement of E1 and E2 in 
postmenopausal women so as to avoid the fluctuation of hormone levels 
during menstrual cycle thereby introducing errors in the analysis.  
1.2 Physiological effects of estrogens 
Estrogens exert important physiological effects on hormone-dependent 
reproductive tissues such as the breast, bone and brain (Figure 1.1). Estrogens 
are responsible for the proliferation and differentiation of the ductal 
epithelium in the breast. The mechanism of action is by inducing mitotic 
activity of ductal cylindric cells, and stimulating the growth of connective 
tissue present in the breast (Porter 1974). Estrogens also exert histamine-like 
effects on the microcirculation of the breast. Due to these effects of estrogens, 
the density of ER in breast tissue peaks in the follicular phase of the menstrual 
cycle and falls after ovulation (Soderqvist, et al. 1993). However, estrogens 
have adverse effects such as stimulating the proliferation of breast-cancer cells.  
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In the bone, both osteoclasts (Oursler, et al. 1991) and osteoblasts 
(Eriksen, et al. 1988) express ERs and are direct targets for estrogens. Overall, 
estrogens are considered as anti-resorptive agents by directly promoting the 
proliferation of osteoblasts and inhibiting the function of osteoclasts. 
Furthermore, estrogen deficiency due to the removal of ovaries in mice led to 
increased production of IL-6, IL-1, and tumor necrosis factor in osteoblasts 
and other bone-derived stromal cells. The presence of these factors stimulate 
osteoclast differentiation indirectly (Jilka 1998). Notably, high expression 
levels of both IL-6 and IL-1 mRNA were found in bone extracts from 
postmenopausal women with osteoporosis (Ralston 1994). Therefore estrogen 
levels that drop dramatically after menopause are known to promote loss in 
bone mineral density and increase risk of fractures in older women. The use of 
estrogen therapy in women with osteoporosis is able to restore bone mineral 
density (Christiansen, et al. 1981) thus reducing the risk of fracture  (Lindsay, 
et al. 1980; Lufkin, et al. 1992). 
 Estrogens are also known to be natural vasoprotective agents. ERs 
have been identified in smooth-muscle cells of coronary arteries (Karas, et al. 
1994) and endothelial cells in various tissues (Venkov, et al. 1996). The 
protective nature of estrogens in coronary arteries is by increasing the 
formation and release of nitric oxide and prostacyclin in endothelial cells 
resulting in short-term vasodilation (Kim, et al. 1999). Estrogens can also 
reduce vascular smooth-muscle tone by opening specific calcium channels 
through a mechanism that is dependent on cyclic guanosine monophosphate 
(White, et al. 1995). The finding that estrogen treatment reduced the 
progression of coronary-artery atherosclerosis in oophorectomized monkeys 
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supports the protective role of estrogens. No observed effects were observed 
on preexisting plaques (Clarkson, et al. 1996). The mechanisms of estrogens 
on the cellular level include; inhibition of apoptosis in endothelial cells 
(Spyridopoulos, et al. 1997) and promotion of their angiogenic activity in-
vitro (Morales, et al. 1995). The favorable findings of epidemiologic studies 
have to be balanced by the lack of benefit of estrogen for secondary protection 
against cardiovascular disease in the Heart and Estrogen/Progestin 
Replacement Study (Hulley, et al. 1998). Despite these evidences, the use of 
estrogen treatment in the postmenopausal period for the prevention of 
atherosclerosis remains controversial (Grodstein, et al. 2000). 
In the nervous system, the brain aromatization hypothesis proposes 
that sexual differentiation of the brain is caused via a surge of gonadotropin 
secretion in women and is dependent on local conversion of androgens to 
estrogens (Naftolin 1994). Although the rate of aromatization of androgen to 
estrogen in the brain is relatively lower compared to other tissues, local 
estrogen production is believed to have critical actions. One example of this is 
the synergistic action of estrogens with neurotrophins that is reflected in 
reciprocal receptor regulation or coupled signaling pathways (Toran-Allerand, 
et al. 1999). Estrogens are thought to have neuroprotective actions in older 
adults, this is supported by evidence that show estrogens induce synaptic and 
dendritic remodeling (Naftolin, et al. 1990) and cause glial activation (Garcia-
Segura, et al. 1999) in brains of adult rats. In other areas of the brain such as 
the neurons of the hippocampus, an area involved in memory, estrogens 
increase the density of N-methyl-D-aspartate receptors and increase neuronal 
sensitivity to input mediated by these receptors (Woolley, et al. 1997). 
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Additionally, estrogens was found to have neuroprotective effects (Green, et al. 
1997) and reduce the generation of beta-amyloid peptides (Xu, et al. 1998) in 
cultured human neuroblastoma cells. Results from epidemiological studies 
suggest that estrogen deficiency is associated with a reduction in cognitive 
function and an increased risk of Alzheimer’s disease in postmenopausal 
women (Henderson 1997). However estrogen administration in a randomized 
trial of women with established Alzheimer’s disease showed no beneficial 
effect (Mulnard, et al. 2000). 
Estrogens also exert its effects in other organ systems (Figure 1.1). In 
the liver, estrogens exert a protective effect on the cardiovascular system by 
increasing levels of  lipoprotein receptors, resulting in a decrease in serum 
concentrations of low-density lipoprotein cholesterol (Karas et al. 1994; 
Paganini-Hill, et al. 1996). In the gastrointestinal tract, estrogens may reduce 
the risk of colon cancer (Calle, et al. 1995). Finally, estrogens can increase 
turgor and collagen production and reduce the depth of wrinkles (Schmidt, et 
al. 1996) in women with menopause.  
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Figure 1.1: Effects of estrogens in different organ systems. (Gruber, et al. 
2002)
Reproduced with permission from (Gruber et al. 2002), Copyright 
Massachusetts Medical Society 
 
1.3 Estrogen signaling pathways 
Estrogen Receptor (ER) α and ERβ are two estrogen receptor subtypes 
encoded by genes on chromosomes 6 and 14 respectively. They are from the 
nuclear receptor family and known as ligand-activated transcriptional factors 
that regulates the transcription of estrogen-responsive genes in the cell nucleus.   
In some organs, ERα and ERβ are expressed in similar levels whereas 
in others, one of the subtypes predominates (Figure 1.2).  For example, both 
breast and bone tissues express similar levels of ERα and ERβ whereas for 
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lung tissues the ERβ subtype predominates. The ligand binding domains of 
ERα and ERβ share 59% homology and this accounts for the differential 
binding of endogenous ligands, exogenous ligands from the diet and anti 
estrogens from drugs. The relative levels of ERα and ERβ in a cell determine 
its response to natural or synthetic agonists and antagonists. An increase in the 
expression of ERβ relative to ERα was shown to inhibit the ERα response to 
E2 by silencing the partial ERα-mediated agonism of tamoxifen and 
potentiating its antagonism (Pettersson, et al. 2000). 
There are two pathways of estrogen signaling, classical genomic 
signaling and non-classical non-genomic signaling. In the classical estrogen-
signaling pathway, estrogen binds to estrogen receptors in the cell and gets 
transported to the nucleus where it binds to specific estrogen responsive 
elements of the promoter regions of the DNA that will be transcribed. The 
relative balance of receptors, coactivators, and corepressors proteins 
determines the responses of this classical pathway. Since the relative 
concentrations of these molecules are cell-specific, estrogens can have vastly 
different functions and actions in different tissues of the same organism. This 
explains the tissue-specific effects of a special class of estrogenic compounds 
also known as selective estrogen receptor modulators (SERMs) (Riggs and 
Hartmann 2003). One such example would be tamoxifen, which acts as an 
antagonist in breast but agonist at bone and uterus, and is clinically used as a 
chemotherapeutic agent in breast cancer patients. 
A second mechanism of action for the classical genomic pathway 
involves interactions between estrogen receptors and other transcription 
factors (tethered pathway of Figure 1.3). Usually, in this pathway, ligand 
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bound estrogen receptor interacts with other transcription factors and alter the 
ability of the transcription factor to influence gene transcription. An example 
of this mechanism is the capacity of liganded-ER complexes and other 
transcription factors like Fos/Jun binding to activator protein-1 and SP-1 
specific protein-1 sites adding to the complexity of ER signaling (Paech, et al. 
1997; Saville, et al. 2000). Changes in gene transcription as a result from these 
classical signaling pathways usually occurs after 30-60 minutes. 
On the contrary, estrogen signaling also occurs through the more rapid 
non-genomic pathways occurring within seconds to minutes. These rapid 
effects are mediated by interactions with components of various cell signalling 
pathways, including adenylyl cyclase, Mitogen-activated protein kinase 
(MAPKs), and phosphatidylinositol 3-kinase (PI3K). The receptors that bind 
sex steroid ligands and initiate these responses can be identical to or different 
from known steroid receptors (Figure 1.3). For example, estrogen can bind 
the G protein–coupled receptor homolog GPR30 or to membrane-bound ERs 
and activate extracellular signal–regulated kinases (ERKs) 1 and 2 resulting in 
transcription of growth promoting genes. (Filardo, et al. 2000).  
In addition, there are estrogen independent genomic signaling 
pathways that involve estrogen receptors.  Protein kinase cascades activated 
by growth factors phosphorylate and activate nuclear estrogen receptors at 
ERE binding sites (Figure 1.3) leading to transcription of target genes. 
 The majority of either ligand bound ERα or ERβ is usually found in 
the nucleus activating gene transcription. However about 2% of these 
receptors are found to associate with the cell membrane.  A novel membrane 
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bound ER; ERα36 was recently discovered and found to be responsible for the 
non-genomic effects of estrogen signaling. ERα36 lacks both transactivation 
domains (AF1 and AF2) but retains portions of ligand and DNA binding 
domains of ERα. It functions as a dominant-negative effector of 
transactivation activities of both full-length ERα (ERα66) and ERβ. ERα36 
primarily localizes to the cytoplasm and plasma membrane, and responds to 
both estrogens and antiestrogens by transducing membrane-initiated signaling 
cascades, stimulating proliferation (Lee, et al. 2008c). 
 In breast cancer, the stimulation of ERα36 by estrogens or anti-
estrogens is through the activation of the MAPK/ERK signaling pathway 
leading to cell proliferation. ERα36 is expressed in both ER positive and 
negative human breast cancer cells and may provide an explanation to why 
some human breast cancers are resistant to or worsened by current anti-
estrogen therapy using tamoxifen (Wang, et al. 2006). 
Similarly in bone cells, ERα36 is reported to be strongly expressed in 
osteoblasts and osteoclasts of postmenopausal women with normal bone 
density and less so in those with osteoporosis. Postmenopausal levels of 
estradiol can activate ERα36 present in bone cells to regulate bone remodeling. 
Using human bone cells in vitro, it was demonstrated that ERα36 was able to 
induce anti-apoptotic signaling on osteoblasts and the opposite in osteoclasts 
through ERK1/2 and ROS pathways (Xie, et al. 2011). 
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Figure 1.2: Schematic view of the distribution of the estrogen receptor 
subtypes ERα and ERβ, in organs.  
 
Reprinted by permission from Macmillan Publishers Ltd: Clinical 
Pharmacology & Therapeutics (Nilsson and Gustafsson 2011b), copyright 
(2011). 
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Figure 1.3: Different pathways of estrogen receptor activation (Heldring, 




Phytoestrogens (isoflavones) from soy comprise mainly of genistein 
and daidzein, are structurally and functionally similar to estradiol (E2) and 
estrone (E1) (Figure 1.5). Epidemiological studies have shown that the 
consumption of phytoestrogens is associated with lower risk of hormone 
dependent cancers such as breast and prostate (Fournier, et al. 1998).  
Other non-hormonal effects of phytoestrogens included and are not 
limited to inhibition of aromatase activity (Rice and Whitehead 2006; Wang, 
et al. 2008), down regulation of protein tyrosine kinase(Akiyama, et al. 1987) 
 12	  
and modulation of gene expression by promoter methylation (King-Batoon, et 
al. 2008). They also have higher affinity for ERβ than ERα (Morito, et al. 
2001) and are known to compete with endogenous estrogens for ER (Tham, et 
al. 1998) thereby explaining their different effects as compared to E2. 
Furthermore, compared to E1 and E2, phytoestrogens’ affinity to the estrogen 
receptors is much weaker (genistein binds to ERα 10,000 fold weaker 
compared to E2) (Gutendorf and Westendorf 2001). However, they are present 
in much higher levels in humans who consume soy products such as in Asians, 
thus having the potential to exert estrogenic/anti-estrogenic effects in the body.  
Figure 1.4: Chemical structures of estrogens and phytoestrogens present 
in the human blood.  
 
Levels of these 4 compounds in serum will be measured using LC-MS/MS. 





1.5 Measurement of Estrogens levels in serum 
Levels of estrogens drop rapidly when a woman transits into 
postmenopausal stage, thus accurate and sensitive measurements of serum 
levels of estrogens especially estradiol are crucial in studies that investigate 
the relationship between estrogen levels and risk of diseases in 
postmenopausal women. Levels of E2 in the low postmenopausal range lies 
within 0 to 110 pM. However, most E2 assays were originally developed for 
use in younger women, which is only accurate for E2 levels greater than 183 
pM. Therefore measurement of E2 levels in postmenopausal women lack 
standardization and accuracy across many different laboratories using 
different kits. 
There are currently two major methods used to measure E2, namely 
indirect and direct assays.  Indirect assays consist of an initial extraction step 
before measurement using radioimmunoassay (RIA) or mass spectrometry. 
The extraction step removes potentially interfering substances especially 
cross-reacting water-soluble steroid conjugates. Gas or liquid 
chromatography-mass spectrometry methods has been considered as a gold 
standard for measurement of low serum E2 levels (Tai and Welch 2005). On 
the contrary, direct assays do not involve extraction thus can be automated and 
require less labor, specimen volume and cost. However they are inaccurate 
due to nonspecific binding of other steroidal compounds with similar 
structures to the antibody or ill-defined matrix effects, leading to 
overestimation of true concentrations. 
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Even though mass spectrometry is considered the reference method for 
measurement of low serum E2 concentrations, many other variables may also 
affect the accuracy of this method.  These include standardization of 
calibration standards, machinery and experimental procedures. For this thesis, 
we used liquid chromatography tandem mass spectrometry for measurement 
of estrone and estradiol levels from serum of postmenopausal women. 
Previous studies that relied on direct assays using immunoassay kits without 
extraction may have underestimated the relationships between endogenous 
hormones and risk of diseases in postmenopausal women due to the inaccurate 
readings or undetectable levels at low range concentrations (Lee, et al. 2006). 
 
1.6 Cell-Based Bioassays  
Bioassays allow the measurement of the cumulative estrogenic activity 
of the whole mixture, whereas chemical or immunoassays analysis only 
allows examination of known and suspected chemicals present in the mixture. 
In complex samples such as sera, many compounds are present and can 
contribute to overall estrogenicity. ER-mediated estrogenic activity can be 
measured using a cell-based assay that is independent of the measurement of 
estradiol concentrations using immunoassays or LC-MS/MS. Diet and 
environmental influences could result in the presence of exogenous estrogenic 
compounds in the blood. These includes dietary intake of phytoestrogens that 
are present in common foods and nutraceuticals such as apigenin (celery), 
fisetin (apples), icariin/baicalein (folk medicines), galangin (ginger), quercetin 
(onions), kaempferol (tea), luteolin (oranges), formononetin/biochanin (red 
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clover), or the intestinal metabolite equol (Oseni, et al. 2008). Similarly a wide 
range of synthetic endocrine disrupting chemicals such as dioxins and 
polychlorinated biphenyls, bisphenol A, pesticides are estrogenic compounds 
that can exert biological effects at minute concentrations. They have the 
potential to provoke synergistic estrogenic mixture effects at low doses that 
could be present in human sera, even at no observed individual effect levels 
(Diamanti-Kandarakis, et al. 2009; Kandaraki, et al. 2011a).  
Measurement of serum estrogens/estrogenic bioactivity includes both 
direct and indirect assays. The methods used to evaluate estrogenic actions 
includes rodent uterotrophic assay, E-screen based on proliferation of estrogen 
sensitive MCF-7 cells, receptor binding competitive affinity assays, induction 
of estrogen regulated genes such as PS2 or progesterone receptor, and reporter 
gene assays based on yeast or human cell lines (Soto, et al. 2006).  Direct 
assays such as receptor binding assays do not assess agonist and antagonist 
activity of the compounds but only measures receptor ligand interactions. 
Indirect assays such as E-screen are able to distinguish between estrogens and 
antiestrogens and are very sensitive; however the assay requires about a week 
to complete and is highly variable. Among these different methods, reporter 
genes driven by ER-responsive promoters in human cell lines can provide data 
that can be quantitated with greater specificity, sensitivity, accuracy and 
precision as well as offer scalability(Paris, et al. 2002a; Wong, et al. 2007b).  
Such ER-driven reporter gene assays have been widely used to 
evaluate environmental samples (Diamanti-Kandarakis et al. 2009) but also 
have been validated for measuring estrogenic activity of serum that contains 
low levels of estrogens such as in postmenopausal women (Wang, et al. 2005) 
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and pre pubertal children (Paris et al. 2002a) indicating it’s high sensitivity.  
In general, a cell line of choice (yeast or human cervical cell line) is 
transfected with both the estrogen receptor and the promoter connected to a 
reporter gene such as luciferase (Figure 1.5). The luciferase reading is then 
quantified against a calibration curve using known concentrations of 17β-
estradiol spiked into charcoal treated control pooled serum. The estrogen 
receptor bioassay developed in our lab is based on HeLa (cervical) cell line as 
it possess only small amounts of ERβ and it is relevant to female reproductive 
system. 
  We used a permanently transfected cell line that is more stable and less 
variable. This bioassay have been shown to be highly correlated (R=0.83) with 
increases in total estrogen levels in sera following ingestion of the estrogenic 
prodrug estradiol valerate (Li, et al. 2009) which was an experiment 
conducted by our laboratory. Specifically, regression modeling indicated that 
our ERα bioassay correlated better with summated estrone and estradiol levels 
compared to either hormone alone, demonstrating the bioassay’s ability to 
reflect the summated activity of at least two estrogens in sera. 
Such cell-based assays have the advantage of measuring the global 
estrogenic activity of all compounds, regardless of whether they are known or 
unknown, agonist or antagonist, exogenous or endogenous present in the 
serum. These estrogenic compounds can act on a relevant physiological 
endpoint that is measureable, i.e., ERα-driven transcriptional activity (Li et al. 
2009; Wong, et al. 2007a). However, this bioassay measures only the classical 
pathway of estrogen receptor activation (Figure 1.3), where estrogen activates 
estrogen receptor alpha then binds to estrogen response elements and results in 
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transcription of estrogen responsive genes  (Figure 1.5).  Furthermore, both 
ERα and ERβ activation can be investigated separately using cell lines that 
overexpress the receptor of interest. 
However, this bioassay only reflects a portion of the total effects of 
estrogen signaling which is the direct pathway of Figure 1.3, non-genomic 
effects of estrogen may also have a role to play especially in breast cancer, hip 
fractures or even lung cancer through membrane receptors such as GPR30 and 
ERα36, non genomic pathways of Figure 1.3.  It is important to note that 
growth factors are present in human serum may activate the estrogen 
independent genomic actions (Figure 1.3). Therefore, the effects of estrogen 
receptor activation through growth factors that are present in the serum may 
have a minor contribution to the overall estrogenic activity of the serum. 
Figure 1.5: Schematic diagram of the estrogen receptor bioassay 
	  
Validated HeLa cell lines co-transfected with plasmids encoding ERα and a 
luciferase reporter gene consisting of 4 tandem copies of Estrogen Response 
Element (ERE) are used for this bioassay. 
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1.7 Differences between Asian and Caucasian Women 
Asian women are different from Caucasian women in many different 
ways that could affect their disease risk profiles. Besides genetic differences, 
the pattern of environmental exposures such as diet, smoking, and use of 
hormone replacement therapy in Asians is different from Caucasians. In terms 
of diet, soy consumption in particular is much higher among Asian women 
compared to Caucasian women in the West (Seow, et al. 1998).  In the Nurses 
Health Study (USA), the prevalence of hormone replacement was as high as 
45%. Interestingly, the authors noted that the relative risk of breast cancer 
associated with increase in hormone levels was higher in women who had 
never used hormone replacement therapy compared to those who had (Key, et 
al. 2002a).  
A recent study examined differences in genetic breast cancer risk 
factors between Asian and Caucasian women and found that BRCA1 
mutations were more common among Caucasians (67 vs. 42 %, p = 0.02) 
conversely BRCA2 mutations were more common among Asians (58 vs. 37 %, 
p = 0.04). More Asians had breast cancer (76 vs. 53 %, p = 0.03); more 
Caucasians had family history of breast cancer (86 vs. 50 %, p = 0.0003). 
Asians had a higher frequency of breast cancer risk-associated alleles in 
MAP3K1 (88 vs. 59 %, p = 0.005) and TOX3/TNRC9 (88 vs. 55 %, 
p = 0.0002)(de Bruin, et al. 2012). 
Furthermore, marked differences in circulating estrogen concentrations 
have been reported between Asian and Caucasian women (Dowsett, et al. 
2000). Although there is an increase trend of smoking in women, the 
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prevalence of smoking in Asian women is still much lower compared to the 
western countries (Samet, et al. 2010). Asians have also distinct 
anthropometric measures such as lower BMI levels that differ from 
Caucasians. Hence, there is a need to repeat such studies among Asian women 
with smaller body size, higher intake of soy products, less likely to smoke and 
also less likely to use hormone replacement such as the Chinese women in 
Singapore.  
 
1.8 Association between Reproductive Factors and Hormone levels  
Reproductive factors such as age of menarche, age of menopause, age 
of first birth, number of children/parity, length of reproductive period (age of 
menopause-age of menarche) have been investigated on its impact on risk of 
diseases in women. In terms of breast cancer, higher parity, older age of 
menarche, early menopause, younger age of first birth are established factors 
associated with reduced risk (Kelsey, et al. 1993). The underlying mechanisms 
of these reproductive factors providing a protective effect against breast 
cancer risk have not been well understood. It is hypothesized that pregnancy 
may cause permanent morphological changes in breast tissue that provide a 
lasting protection against breast cancer, and that this protection is further 
strengthened by increasing number of pregnancies (Russo, et al. 2005). 
Furthermore, reproductive period may determine the cumulative exposure to 
menstrual factors, and the lower the total number of regular menstrual periods 
may reduce the exposure to reproductive hormones and reduce breast cancer 
risk independent of factors related to pregnancy (Britt 2012).  
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Several studies have thus looked into the association between these 
reproductive risk factors and hormone levels in postmenopausal women. The 
results show that high parity is associated with lower estrone sulfate levels in 
postmenopausal women (r=-0.15, P=0.03).  Younger age at first childbirth is 
associated with increase free estradiol (r=-0.17, P=0.02) (Hankinson, et al. 
1995a). Older age at menarche was associated with lower androstenedione, E1, 
E2 and free E2 levels in postmenopausal women (Madigan, et al. 1998). In 
another study, higher parity was associated with higher SHBG levels and with 
lower free E2 levels. Women with 4 or more children had 20% lower free E2 
and 38% higher SHBG concentrations compared with women with one child 
(P for trend = 0.02 and 0.01, respectively) (Chubak, et al. 2004). These results 
indicate that the mechanism by which reproductive factors influence risk of 
hormone related diseases could be through modulating hormone concentration 
levels at postmenopausal period. 
The most recent study conducted by the endogenous hormones and 
breast cancer collaborative group looked at breast cancer risk factors and 
circulating hormone concentrations in postmenopausal women controls in 13 
prospective studies. In this study, they did not manage to find any strong 
association between hormone concentrations and reproductive factors (Key, et 
al. 2011). Only women who had older age of menarche (≥14 years) were 
associated with 6% lower estradiol levels compared to women with younger 
age of menarche (<12 years). These suggest that the effect of reproductive 
factors on breast cancer risk may not be attributable to postmenopausal 
hormone levels and that these two factors are independent in breast cancer risk 
prediction.  Reproductive factors may mediate the duration rather than level of 
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exposure to sex hormones (Key and Pike 1988) and result in long-term effects 
on sex hormone levels in premenopausal women (MacMahon, et al. 1982). 
Reproductive factors could also affect breast cancer risk by hormonally 
mediating long lasting changes in breast tissue structure (Russo et al. 2005) or 
by other unknown mechanisms affecting a women’s risk of breast cancer 
independently of estrogen levels during postmenopausal period. 
1.9 Objectives 
	   The objective of this thesis is to investigate the role of estrogenic 
biomarkers in their association with the risk of hip fracture, breast cancer and 
lung caner in postmenopausal women in Singapore. 
Previous studies have looked at the association between reproductive 
factors and risks of diseases in women such as breast cancer and lung cancer. 
Furthermore, reproductive factors are also shown to be associated with levels 
of estrogens in postmenopausal women. The ability of estrogen levels to 
predict the risk of diseases in postmenopausal women can be due to it’s direct 
independent effects or it’s dependent effects on reproductive factors. Thus, the 
objective of this thesis is to examine the role of estrogens in association with 
disease risk/survival in postmenopausal Chinese women in our cohort.  
The decision to focus on postmenopausal women is two-fold. First, the 
numbers of premenopausal women in our cohort in relatively small and 
therefore sub-analysis may not be appropriate. Second, hormone fluctuations 
during menstrual cycle of premenopausal women may result in errors during 
analysis. 
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To the best of our knowledge, such a comprehensive study on the 
impact of both estrogen and phytoestrogen levels and ER mediated estrogenic 
activity on risk/ survival of hip fractures, breast cancer and lung cancer has 
never been done in Asian women, who have different risk profiles from their 
western counterparts. Hence, our proposed study among postmenopausal 
women in Singapore is a novel study with potentially ground-breaking 
findings in the aetiology and risk/survival prediction of hip fractures, breast 
cancer and lung cancer among Asian women. 
Studies evaluating the use of the estrogenic activity assays and sera 
estrogenic compounds levels, as predictive tools of disease risk will require 
sera collected from disease patients before disease diagnosis. Such 
epidemiologic studies are therefore only possible in large-scale cohort studies 
where blood from participating women has already been collected at baseline 
before the development of disease. With the exception of lung cancer where 
samples are collected from hospital based case-control study, both hip fracture 
and breast cancer samples are from the Singapore Chinese Health Study 
cohort. These studies will directly link estrogenic activity to disease 
development in humans and strengthen the notion that the estrogen signaling 
pathways are a major contributor to etiology of the disease. For the lung 
cancer case control study, we looked at how estrogenic activity and or levels 
are associated with survival in postmenopausal Chinese women.  
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CHAPTER 2: ROLE OF ESTROGENIC FACTORS IN HIP 
FRACTURE RISK 
The contents of this Chapter are based on the Author’s peer-reviewed 
publication in: 	  




Osteoporosis is a global problem that has serious public health 
implications. Osteoporosis often leads to fracture of the hip, spine or wrist 
after only a minor injury. These fractures lead to loss of function and disability 
and have great impact on both the patients and their family. Among these 
fractures, hip fractures have the most devastating results, and the incidence 
rate of hip fracture is commonly used to indicate the prevalence of 
osteoporosis. Menopause is one of the risk factors of osteoporosis in elderly 
women. Due to its rapidly ageing population, Singapore needs to have greater 
awareness of good bone health. In Singapore the incidence of hip fracture has 
increased 1.5 times in men and 5 times in women since the 1960s (Koh, et al. 
2001). This rise in incidence is consistent with secular trends seen in many 
countries. Age-adjusted rates among women over the age of 50 years are 
currently among the highest in Asia, and approaching those of the West. 
Furthermore, the consequences of hip fracture are severe. A recent local study 
showed that about 1 in 5 persons died within a year of sustaining an 
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osteoporotic hip fracture and 1 in 3 became wheelchair bound or bedridden 
(Lee, et al. 2007). 
 
In elderly women, hip fractures secondary to osteoporosis are a 
significant cause of mortality and morbidity (Haentjens, et al. 2010). After 
menopause, the risk of osteoporotic fractures increases exponentially, and this 
observation has led to the development of a unitary model for estrogen 
deficiency as a cause for bone loss and consequent fractures (Riggs, et al. 
1998). This was supported by an early epidemiological study, which found 
that women with detectable estrogens in the blood had a lower risk of 
osteoporotic hip fractures (Cummings, et al. 1998). However, this finding was 
contrasted by another later study indicating that the effect of free estradiol on 
fracture risk was attenuated when adjusting for testosterone and sex hormone 
binding globulin (SHBG) levels; the association with decreased hip fracture 
risk was also no longer evident when further adjusted for body mass index 
(BMI) (Lee, et al. 2008b). Similarly, a study in a French population found that 
higher free estradiol was associated with a lower risk of hip fracture was no 
longer significant after adjustment for weight (Chapurlat, et al. 2000a). Recent 
evidence has led to a significant shift from an estrogen-centric view as a cause 
of osteoporotic fractures to one of aging and oxidative stress (Manolagas 
2010). This paradigm shift that aging is the pivotal determinant of bone mass 
and strength was backed by the finding that age-related bone loss begins in the 
third decade in estrogen-replete women (Hui, et al. 1988b). Independent of 
estrogens, factors including changes in collagen quality (Bailey and Knott 
1999), reactive oxygen species (Manolagas 2010), progesterone deficiency 
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(Seifert-Klauss and Prior 2010) and polymorphisms of genes of the receptor 
activator of NFκB ligand signaling system (Dong, et al. 2009) have been put 
forth as critical determinants of bone strength. Therefore, the role of estrogens 
at low physiological postmenopausal levels in hip fracture risk remains 
controversial. In particular there exists limited data on rapidly aging Asian 
populations, who have different estrogenic and anthropometric profiles 
compared to Caucasians (Ursin, et al. 2001). 
Experimental studies suggest that estrogenic compounds exert their 
effects by binding and stimulating estrogen receptors (ER) to prolong survival 
of osteoblasts and induce apoptosis in osteoclasts, thereby reducing bone 
resorption and promoting bone health (Manolagas 2000). ERα is the 
predominant subtype in post-menopausal bone specimens (Batra, et al. 2003) 
and there is evidence that mice with normal ERα, but non-functional ERβ 
(βERKO), have normal bone mineral density and trabecular structure (Nilsson 
and Gustafsson 2011a). The role of ERα in bone homeostasis is shown when 
bone loss is prevented in ovariectomised rats treated with ERα, but not ERβ 
selective agonists (Hertrampf, et al. 2008; Seidlova-Wuttke, et al. 2008), thus 
indicating the critical role of ERα in bone homeostasis.  
Exogenous estrogenic compounds such as phytoestrogens consumed in 
the diet play a role in hip fracture risk. Randomized controlled trials 
conducted in the West have shown that Hormone Replacement Therapy 
(HRT) is associated with a decreased risk of hip fractures (Cauley, et al. 2003; 
Jackson, et al. 2006). In addition, there are several studies linking soy intake 
and the risk of hip fracture in Asian populations. Soy consumption reduces the 
risk of hip fractures in a study conducted in Shanghai (Zhang, et al. 2005). 
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Another recent paper showed that high soy intake in Singaporean Chinese 
women is found to be protective against hip fractures (Koh, et al. 2009b). 
However three randomized controlled trials investigating the effects of soy 
isoflavones supplementation on bone mineral density (BMD) did not manage 
to show an effect of soy isoflavones in reducing bone loss. (Alekel, et al. 
2010; Kenny, et al. 2009; Wong, et al. 2009). The main limitations of these 
intervention studies were the short time frame of assessment that lasted 
between 24-36 months, which may have been insufficient to show significant 
improvements in bone health and basing the outcomes on bone health on a 
single parameter, namely BMD.  
In this study, using prospectively collected serum samples from the 
Singapore Chinese Health study, we aimed to determine the contribution of 
blood estrogens,  phytoestrogens and ERα mediated bioactivity to hip fracture 




The subjects were participants of the Singapore Chinese Health Study, 
a population-based, prospective cohort of 63,257 Chinese subjects (including 
35,298 women). Subjects, aged 45-74 years, were recruited between April 
1993 and December 1998 from residents of government-subsidized housing 
schemes, in which the majority (86%) of Singaporeans resided at the time of 
recruitment (Hankin, et al. 2001). Study subjects were restricted to the two 
major Chinese dialect groups: Hokkien and Cantonese, who originated from 
two contiguous prefectures in southern China. The Institutional Review 
Boards at the National University of Singapore and the University of 
Minnesota approved this study.  
At recruitment, subjects were interviewed in-person using a structured 
questionnaire that asked for information including demographics, use of 
tobacco, menstrual (including menopausal status) and reproductive (including 
use of menopausal hormone therapy) histories (women only), medical history, 
as well as a dietary component assessing current intake patterns. Respondents 
were asked to choose from predefined frequency and portion size categories 
for each of the 165 listed food/beverage items that he/she consumed during the 
past 12 months. We used the Singapore Food Composition Table to estimate 
average daily intake of 96 nutrient and non-nutrient compounds for each study 
subject, including soy isoflavones and calcium intakes (Hankin et al. 2001). 
The food frequency questionnaire was subsequently validated against a series 
of 24-hr diet recalls (Hankin et al. 2001). Between April 1994 and December 
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1999, blood and single-void urine specimens were collected from a random 
3% sample of study enrollees. A 20-ml blood sample was obtained from each 
consenting subject. Immediately after blood collection, the tubes were put on 
ice during transport from the homes of the subjects to the laboratory. All of 
the specimens were then separated into their various components such as 
plasma, serum, RBCs and buffy coat and subsequently stored in a liquid 
nitrogen tank at -180oC until August 2001, after which they moved it to a -
80oC for long term storage(Koh, et al. 2003b). Between January 2000 and 
April 2005, we extended our biospecimen collection to all surviving cohort 
members and collected biospecimens from 32,543 subjects, representing a 
consent rate of about 60% of surviving cohort participants at that time.  
 
Case ascertainment 
Women in the Singapore Chinese Health Study who donated blood 
samples prior to hip fracture were eligible for this study. We identified 
incident hip fracture cases through the MediClaims Database, which is a 
nationwide hospital discharge claims system. This database was set up in 1990 
to comprehensively capture inpatient discharge information (including 
diagnosis) from all hospitals in Singapore (Heng, et al. 2000). We excluded 57 
prevalent cases of hip fracture among female cohort participants and identified 
871 incident cases of hip fracture as of 31 December 2008.  The diagnoses of 
hip fracture cases were verified by cross-checking with records of the 
appropriate surgical procedures or manual review of medical records. 
Additionally, we excluded cases of traumatic fractures from road traffic 
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accident or pathological fractures due to malignant metastasis to the femur. 
For this study, we included 140 cases who had donated blood samples for 
research before their fractures occurred.  We compared the baseline 
characteristics of women who gave blood prior to fracture (included in this 
study) with those who either did not give or gave blood after the fracture (not 
included in this study). These two groups were similar in baseline factors such 
as age at fracture (mean age 73 years for both groups), BMI (mean of 23 




We randomly select two control subjects among all female cohort 
participants who had donated blood samples, and who were alive and free of 
hip fracture history at the time of hip fracture of their index case. The chosen 
controls were matched to the index case on age at study enrollment (±3 years), 
dialect group (Hokkien, Cantonese) and date of study enrollment (±2 year), 
date (±6 months) and body mass index (BMI) at the time of biospecimen 
collection. There were two cases where only one eligible control was found 
for each of them.  Hence, the study consists of a total of 140 hip fracture cases 






Serum samples of a given matched set (containing the samples from 
the case and one or two matched controls) were arranged in random order, 
identified only by unique codes, and tested in the same laboratory batch for all 
measurements.  Laboratory personnel were blinded to case or control status of 
the samples.  Serum samples contained in straws were thawed at 4ºC and 
individually filtered via 0.22 µm sterile cartridges. Filtered sera were collected 
in aliquots for measurements of estrone, estradiol, SHBG, and ERα-mediated 
estrogenic activity. 200µl of serum is used for measurement of estrone and 
estradiol, 10µl is used for measurement of SHBG and 25µl is used for the ERα 
bioassay. The filtering is essential to make the serum sterile for subsequent 
bioassays experiments. 
 
Detection of E1, E2, Genistein and Daidzein. 
Levels of E1, E2, genistein and daidzein in the serum were measured 
using LC-MS/MS. For the measurement of gensistein and daidzein 2µl each of 
glucuronidase and sulphatase were added to 200µL of thawed serum samples 
and incubated at 37oC for 2hrs. This allowed deconjugation of conjugated 
flavonoids hence measurement of total flavonoids in the serum. Samples were 
spiked with 10ul of internal standards containing d4E1, d5E2 at 1nM, 
d4genistein, d4daidzein at 10nM final concentration. Samples will be extracted 
with 1ml of ethyl acetate three times. The extract will be dried under nitrogen, 
redissolved in 50 µL of sodium bicarbonate buffer (100 mmol/L, pH 11.4), 
and finally derivatized with 50 µL of 1 g/L dansyl chloride in acetone at 60°C 
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for 5 min. 40 µL of this sample was injected twice into an API 3000 triple-
quadrupole (ABI-Sciex) LC-MS/MS system to get two readings. The analytes 
of interest were monitored by Multiple- Reaction-Monitoring of product ion 
pairs and total run time for each sample was 22mins. The chromatographic 
separation was performed on a 150 × 2.0 (i.d.) mm Phenomenex Synergi 
4µMax-RP column.  
Concentrations for E1 were quantified using a five-point linear 
calibration curve from 25pM to 1000pM. Concentrations of E2 were 
quantified with a six-point linear calibration curve from 10pM to 1000pM. 
Calibration curve was obtained from peak area ratio for compound to internal 
standard against the concentration. Concentrations for genistein and daidzein 
were quantified using eight-point quadratic calibration curve with 
concentrations ranging from 250pM to 1µM. Results were calculated from the 
average of two readings taken from each sample. The lower limits of 
quantitations were 10 pM estradiol and 25 pM estrone and 250 pM for both 
daidzein and genistein spiked into 200 µL of blank serum. The ranges of 
coefficients of variation for interday and intraday assays were 1.2-13.3% and 
3.9-14.5% for 10 pM to 1000 pM estradiol, 1.7-11.5% and 1.3-15.7% for 25 
pM to 1000 pM estrone, 1.7 – 16 % and 0.4 – 9.7 % respectively from 250 pM 
to 1 µM for daidzein and 0.1 – 14.7 % and 0.5 – 13.9 % respectively from 250 
pM to 1 µM for genistein. 
 Extraction is an important process when done properly can enable 
high and reproducible recovery of the analytes. This will in turn help to 
improve the sensitivity in detection. Liquid-liquid extraction was chosen as 
the method of extraction over the solid phase extraction (SPE). Through the 
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selection of an appropriate extraction solvent, it enables reduction in the 
background noise, which will help to improve the signal-to-noise (S/N) ratio. 
Furthermore, it is also a very convenient method to treat the limited volumes 
of the human serum samples. Ethyl acetate was chosen as the extraction 
solvent because of its low toxicity, good solubility and lower cost compared to 
solid phase extraction cartridge. After three times extraction and drying with 
nitrogen gas, compounds were reconstituted in 50µl of sodium bicarbonate 
buffer at 100nM, pH 11.4 and 50µl of dansyl-chloride and incubated in a 60oC 
oven for 5mins for the derivatization reaction. After derivatization, the 
samples were transferred to autosampler glass vials. The derivatization 
reaction is used to increase the sensitivity for detection by increasing the 
ionization of E1 and E2. 
 HPLC was carried out on an Agilent Technologies Model 1200 liquid 
chromatograph system with a binary pump (Palo Alto, CA, USA). A 
Phenomenex Synergi (Torrance, CA) 4 µm Max-RP 80A (150 mm × 2 mm, 4 
µm particle size) column was used for separation. The mobile phase consisted 
of two eluents, solvent A (ultrapure water with 0.05 % formic acid) and 
solvent B (acetonitrile with 0.05 % formic acid) delivered at a flow rate of 
0.35 ml/min and at column temperature at 25oC. 40 µl of each sample was 
injected into the LC-MS/MS, after which the injector needle was washed with 
flush port with washing liquid (methanol with H2O and formic acid (50: 50: 
0.1) (v %: v %: v %)). The initial condition of 40 % solvent A was maintained 
for 8 mins before injection for equilibration of pressure in the column. The 
same solvent condition was maintained for another 3 mins after injection 
before decreasing to 10 % of solvent A. This condition was maintained for the 
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next 9 mins. The first 3 mins after the injection was computed to go to waste. 
Thereafter, the valve was switched to MS. The total run time was 20 mins, 
including 8 mins of equilibration. During the detection, the samples were kept 
in the autosampler at 25oC. 
The HPLC eluent was analyzed by an API 3200 triple quadrupole 
mass spectrometer (ABI-Sciex, Toronto, Ontario, Canada) that is equipped 
with a turbo ion spray source and operated under positive ion mode. Multiple 
reaction monitoring (MRM) was used for the quantification.  The MRM 
transitions used were m/z 506 → 171 for dansyl-E2, m/z 504 → 171 for 
dansyl-E1 and for the internal standards, m/z 511 → 171 for dansyl-d5-E2, m/z 
508 → 171 for dansyl-d4-E1. Nitrogen gas was used as the curtain and 
collision gas. All data were recorded and processed by using the Analyst 
software Version 1.4.2 (ABI-Sciex, Foster City, CA). Calibration standards 
were prepared in charcoal stripped male human serum and final calibration 
curves were constructed using the least squares regression method. 
 
 
Detection of SHBG 
Serum SHBG concentrations were measured using a time-resolved 
immunofluorometric assay (Niemi, et al. 1988). The intra- and inter-assay 
CVs were less than 8% for 6-200 nM SHBG. There are currently two methods 
for calculation of amount of unbound estradiol present in the serum based on 
SHBG levels. The first method is based on a mathematical model with an 
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assumed constant level of albumin and affinity constants of SHBG and 
albumin for estradiol (Sodergard, et al. 1982b). The second method is based 
on the relationship between SHBG and free estradiol obtained by experiments. 
We will use the second method of calculation in all the studies conducted in 
this thesis. Details as follows, percent free estradiol was calculated from 
serum SHBG levels based on the following regression model: Percent free 
estradiol = -0.01533 × serum SHBG + 2.921. The regression model is based 
on measurement of non-protein bound estradiol using centrifugation 
ultrafiltration dialysis and SHBG using immunoradiometric assay in serum of 
control subjects(Langley, et al. 1985).  Free estradiol level for each subject 
was then computed as the product of percent free estradiol and total estradiol 
level. This assay was conducted in our collaborator’s lab from University of 
British Columbia, Vancouver. 
 
Estrogen Receptor bioassays 
Biological activity of estrogens in serum was assessed using a 
validated estrogen-driven recombinant cell bioassay (Wong et al. 2007a). 
Human uterine cervical HeLa cells (ATCC) stably expressing recombinant 
ERα protein and 4 tandem copies of estrogen response element coupled to a 
luciferase gene were exposed to test sera. Cells were maintained in 300µg/ml 
of geneticin and 100µg/ml of hygromycin to ensure stable expression of 
transfected plasmids.  
ERα responsive cells were passaged, plated in a 96 well plate in 10% 
charcoal treated FBS and allowed to adhere overnight. Culture medium was 
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then removed and replaced with incremental amounts of estradiol in 10% male 
human serum (Sigma) stripped of steroids using charcoal treatment for 
calibration standards. Stock solutions of estradiol were prepared in DMSO and 
diluted 500 times in Eagle’s Minimum Essential Medium containing 10% 
male human serum and duplicates of each concentration were included in the 
plate. Similarly test serum was also diluted to 10% using Eagle’s Minimum 
Essential Medium and added to the cells in duplicates.  Baseline level of 
estradiol in charcoal treated human serum is about 13-20pM tested using LC 
MS/MS.  
After an incubation period of 24 hours, medium was decanted, and 
cells were washed with phosphate saline buffer and lysed with Mammalian 
Protein Extraction Reagent (MPER) from Pierce. Luciferase activity was 
measured using the Luciferase Assay System (Promega) on the Glomax 96-
well Microplate Luminometer (Promega). All test sera were tested on the 
same day in the same batch. Calibration standards and QC samples were 
included in every 96-well plate. Calibration curves were fitted with the 
regression method that visually best fits the points within the range of the test 
samples and maximizes the correlation coefficient (R2) value. The R2 value for 
ERα and ERβ ranged from 0.96-0.99. Total estrogen-mediated activity was 
calculated based on the average luminescence readings for each test sera and 
was expressed as pM estradiol equivalent obtained by interpolation from 
calibration curves in each plate. Microsoft Excel software was used for curve 
fitting and interpolation.  
 For the ERα bioassay, the calibration curve ranged from 5pM to 70pM, 
with intra- and inter-assay RSDs of 6% and 14%, respectively. For the ERβ 
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bioassay, the calibration curve ranged from 5pM to 250pM and the intra- and 
inter-assay RSDs were 8.1% and 16%, respectively (Li et al. 2009; Wong et al. 
2007a).  
 Assays were accepted if QC samples had relative errors of <30%. If 
the relative error was >30%, the assay would be repeated.   The mean (SD) of 




We used the chi-square and Student’s t-tests to compare the 
distributions of selected demographic, lifestyle and dietary factors between 
cases and controls. We found that the distributions of all biomarkers measured 
were markedly skewed with a long tail toward high values, which were 
corrected, to a large extent, by transforming the original values to logarithmic 
values. Therefore, formal statistical test was performed on logarithmically 
transformed values, and geometric (as opposed to arithmetic) means are 
presented.  The mixed effect model method taking into account matching  was 
used to examine the differences in the concentrations of serum biomarkers 
between hip fracture cases and control subjects. The conditional logistic 
regression method was used to examine the associations between serum 
biomarkers measured and risk of hip fracture. Study subjects were grouped 
into quintiles of individual serum parameters based on their distributions 
among control subjects. The magnitude of the association was assessed by 
odds ratio (OR) and its corresponding 95% confidence interval (CI) and P 
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value. The following covariates (potential cofounders) were included in all 
regression models: age at blood draw, level of education (no formal education, 
primary, secondary or higher); weekly vigorous work or strenuous sports (yes, 
no), BMI (kg/m2), number of cigarettes smoked per day (never smoker, 1-12, 
13-22, or ≥23), number of years of smoking (never smokers, 1-19, 20-39 or 
≥40), self-reported histories of stroke or diabetes mellitus at baseline (yes, no), 
total calcium intake from food and supplement (quartiles), total isoflavone 
intake from soy food (quartiles), and use of menopausal hormone therapy (yes, 
no).  
Statistical analyses were performed using the SAS version 9.1 software. 





Part 1: Cell based bioassay 
Figure 2.1: Immunoblot of ERα and ERβ proteins in stably transfected 
HeLa cells.  
 
Total cellular proteins were extracted from ERα or ERβ stably 
transfected HeLa cells, and the presence of ERα and ERβ proteins was 
detected with specific monoclonal antibodies. MCF-7 and MDA-MB-231 cell 
lysates were used as a positive and negative controls for ERα respectively. 
HeLa cells are original cells without any transfection of ERα or ERβ. 
Expression levels of ERα or ERβ in these recombinant cell lines were 
confirmed with immunblotting. Protein extracts were prepared by lysis in 
RIPA buffer containing (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 50 mM 
NaF, 0.1 mM Na3VO4) and protease inhibitor cocktail (Roche, Indianapolis, 





membrane (Millipore, Billerica, MA, USA) and probed with indicated 
antibodies. Antibodies used in this study include: anti-ERα  (Santa Cruz, Santa 
Cruz, CA, USA), anti-ERβ  (Santa Cruz), β-actin (Sigma, St. Louis, MO, 
USA). 
Strong expressions of ERα or ERβ protein were detected in the ERα or 
ERβ cell lines respectively. HeLa cells do not express ERα and the ERβ-stable 
cell line does not contain any detectable ERα protein. HeLa cells do express 
low levels of ERβ and the ERα-stable cell line reflects this, although the 
predominant receptor is ERα.  
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Figure 2.2: Dose-dependent activation of luciferase reporter gene in ERα 





Table 2.1: Summary of EC50 values. 
 
 
ERα or ERβ cells were exposed to increasing dose of estradiol and 
estrone dissolved in culture medium supplemented with 10% charcoal-
stripped FBS for 24 h. Results are expressed as percentage relative to dose of 
maximal activation of estradiol which is 10nM and presented as mean ± SEM.  
Both E1 and E2 exhibited sigmoidal dose-response behavior in both cell lines 
in the presence of natural ligands E1 and E2. The EC50 value of E2 is about 
10-20 times higher than that of E1 in both cell lines. These show that E1 is a 









 EC50 values 
Assay Estrone Estradiol 
ERα 4.784nM 0.208nM 
ERβ 5.15nM 0.408nM 
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Figure 2.3: Comparison of Dose response curves of estradiol in ERα and 
ERβ cell lines 
 
E2 had a higher activation in ERα as compared to ERβ as the EC50 is 
2 times lower in ERα bioassay as compared to the ERβ bioassay. The 
sensitivity of ERβ bioassay is lower as compared to ERα and ERβ was also 
shown to be less active on gene transcription than ERα in cell-based bioassays 




E2 Dose Response Curves

















Figure 2.4: Representative calibration curves of ER-driven reporter gene 
bioassays for quantification of ER- mediated bioactivity of serum samples. 
 
The calibration curves for the human serum samples are based on the 
lower range of the dose response curves of these both bioassays using 
estradiol as the ligand. A quadratic curve is used to fit the curves as it gives 
the best R2 value. The R2 value ranges from 0.96 to 0.99 in all the calibration 
curves.  
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Part 2: Role of estrogenic biomarkers and risk of hip fracture 






Age (years) at blood taken  69.3 (7.2) 68.8 (7.0) 0.498 
Body mass index (kg/m2)   23.4 (3.5) 23.5 (3.7) 0.948 
Dialect (%)     0.939 
   Cantonese 77 (55.0) 154 (55.4)  
   Hokkien 63 (45.0) 124 (44.6)  
Level of education (%)    0.872 
    No formal education 63 (45.0) 127 (45.7)  
    Primary school  58 (41.4) 109 (39.2)  
    Secondary and above 19 (13.6) 42 (15.1)  
History of stroke (%)    0.027# 
No 136 (97.1) 277 (99.6)  
Yes 4 (2.9) 1 (0.4)  
History of diabetes mellitus (%)    0.020# 
No 112(80.0) 246(88.5)  
Yes 28(20.0) 32(11.5)  
Cigarette smoking (%)    0.829 
    Never smokers 122 (87.1) 242 (87.1)  
Former smoker 5 (3.6) 13 (4.7)  
    Current smokers 13 (9.3) 23 (8.3)  
Weekly moderate activity (%)    0.814 
No 107 (76.4) 208 (74.8)  
0.5-3 hours/week 16 (11.4) 30 (10.8)  
4+ hours/week 17 (12.1) 40 (14.4)  
Soy isoflavones (mg/1000kcal/day)  11.6 (8.4) 12.4 (10.3) 0.727 
Calcium (mg/1000 kcal/day)  293.9 (122.9) 292.3 (122.6) 0.776 
Use of menopausal hormone therapy (%) 2 (1.4) 6 (2.2) 0.607 
Note: Figures indicate mean (standard deviation) for continuous data and 
number (percent) for categorical data. 
# indicates P value <0.05. 
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In this case-control study of post-menopausal women nested within the 
prospective cohort of the Singapore Chinese Health Study, 140 cases of hip 
fractures were compared to 278 controls without hip fracture. We compared 
the baseline characteristics of women with hip fracture and women without 
hip fracture. As reported previously using data from the entire cohort of 
women (Koh, et al. 2010; Koh, et al. 2009a), hip fracture cases were more 
likely to be current smokers, spend less time on physical activity, and have 
lower dietary intake of soy isoflavones and higher dietary intake of calcium, 
although these differences did not reach statistical significance in this 
substudy. Cases were more likely to have a history of stroke (2.9% vs 0.4%, 
P=0.027) and diabetes (20.0% vs 11.5%, P=0.020) compared to controls.  
Patients with hip fracture and control subjects were comparable in terms of 
mean age at blood sampling, BMI, dialect group and levels of education 
(Table 2.2). The mean time interval from blood draw to the occurrence of 
fracture was 4.4 (SD 2.5) years and the mean age of cases at the time of 
fracture occurrence was 73.7 (SD 7.1) years. The use of hormone replacement 
therapy was not significantly different between both groups (1.4% for cases 
and 2.2% for controls) (Table 2.2). All the women reported that they were 
postmenopausal at the time of blood draw with the exception of one case and 
one control. However, these two women were 54 and 51 years old, 
respectively, at the time of blood draw and their low serum estrogen levels 
indicated that they were perimenopausal at that time. Results remained 
essentially the same when we repeated our statistical analysis with the 
exclusions of these two women.  
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Table 2.3: Geometric means (95% Confidence Interval) of serum 
estrogenic parameters in Hip Fracture cases and controls   
 






E1 (pM) 131.24(117.58-146.48) 138.14(127.84-149.26) 0.460 
E2 (pM) 48.22(43.42-53.56) 56.18(52.16-60.48) 0.022# 
SHBG (nM) 34.98(32.32-37.86) 32.92(31.12-34.82) 0.224 

















Daidzein (pM) 6587.4(4858.4-8931.8) 7259.3(5850.71-9007.1) 0.613 
 
* Test was using general linear model that retained the matched case-control sets 
with adjustment for level of education, physical activity, body weight, cigarette use, 





Hip fracture cases tended to have lower circulating estrone, estradiol, 
free estradiol and ERα-mediated estrogenic activity, but higher serum SHBG 
levels than controls (Table 2.3). The difference in the concentration of serum 
estradiol and free estradiol between cases and controls was statistically 
significant. Hip fracture cases also tended to have lower levels of soy 
phytoestrogens genistein and daidzein compared to controls (Table 2.3). This 
is similar to the baseline characteristics where soy intake by questionnaire data 
is lower in cases compared to controls (Table 2.2).  
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Table 2.4:  Serum estrogenic parameters and risk of hip fracture. 
 
Biomarker Range Cases Controls Odds Ratio (95% CI)* 
Estradiol         
Q1 <34.5 29 54 1.00 
Q2 <43.2 34 55 1.19 (0.59- 2.40) 
Q3 <53.9 29 55 1.14 (0.55-2.35) 
Q4 <76.1 27 55 0.94 (0.46-1.92) 
Q5 ≥76.1 19 55 0.56(0.25-1.25) 
P for trend       0.128 
Estrone         
Q1 <78.1 29 54 1.00 
Q2 <112.0 24 55 0.78 (0.38-1.59) 
Q3 <141.0 30 54 1.06 (0.52-2.17) 
Q4 <232.5 37 56 1.21 (0.60-2.44) 
Q5 ≥232.5 18 55 0.68 (0.31-1.50) 
P for trend       0.823 
SHBG         
Q1 <20.7 26 55 1.00 
Q2 <29.0 26 55 0.85 (0.40-1.80) 
Q3 <38.8 22 55 0.93 (0.46-1.89) 
Q4 <54.5 34 55 1.52 (0.74-3.09) 
Q5 >=54.5 30 55 1.34 (0.59-3.08) 
P for trend       0.219 
Free Estradiol         
Q1 <0.78 36 54 1.00 
Q2 <1.03 32 55 0.80 (0.41-1.57) 
Q3 <1.26 23 55 0.52 (0.25-1.08) 
Q4 <1.70 23 55 0.59 (0.28-1.21) 
Q5 ≥1.70 22 55 0.43 (0.20-0.94) 





Q1 <13.9 38 55 1.00 
Q2 <14.2 30 55 0.82 (0.43-1.59) 
Q3 <15.0 25 55 0.60 (0.30-1.19) 
Q4 <15.3 25 55 0.58 (0.28-1.17) 
Q5 ≥15.3 20 55 0.50 (0.23-1.11) 
P for trend       0.048# 
Genistein         
Q1 <5620 27 54 1.00 
Q2 <31100 35 55 1.45 (0.75-2.80) 
Q3 <72050 18 55 0.61 (0.30-1.27) 
Q4 <182500 32 55 1.21 (0.61-2.40) 
Q5 ≥182500 26 55 0.86 (0.42-1.78) 
P for trend       0.527 
Daidzein         
Q1 <1240 27 54 1.00 
Q2 <3885 28 55 1.05 (0.55-2.03) 
Q3 <11700 23 55 0.88 (0.44-1.76) 
Q4 <37200 35 55 1.27 (0.64-2.52) 
Q5 ≥37200 25 55 0.76 (0.37-1.56)  
P for trend       0.667 
 
* Conditional logistic regression; adjusted for age at blood taken, level of 
education (no formal education, primary, secondary or higher), weekly 
vigorous work or strenuous sports (yes, no); BMI (kg/m2), number of 
cigarettes smoked per day (never smoker, 1-12, 13-22, or ≥23), number of 
years of smoking (never smokers, 1-19, 20-39 or ≥40), total calcium intake 
from food and supplement (mg/1000 kcal/day) (quartiles), self-reported stroke 
and diabetes at baseline, and total isoflavone intake from soy food (quartiles) 
(except for genistein and daidzein levels), and use of menopausal hormone 
therapy(yes, no) (except for genistein and daidzein levels) . 





To identify threshold effects, cases were grouped into quintiles based 
on distributions of serum parameters among control subjects. The 
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relationships between decreasing hip fracture risk and increasing free estradiol 
and ERα-mediated estrogenic activity were statistically significant (Table 2.4). 
Conversely, there was no clear association between serum estrone, SHBG 
levels and phytoestrogen levels and risk of hip fracture. The risk estimates for 
the association between free estradiol and hip fracture risk remained 
essentially the same after adjustment for SHBG; compared to the lowest 
quintile, the OR (95% CI) of hip fracture risk for the highest quintile of free 
estradiol was 0.44 (0.19-1.01) (p for trend = 0.034).  
 
Table 2.5: Association between ER alpha activity, free estradiol and risk 
of hip fractures 
 
Biomarkers ER alpha activity  Free estradiol 
 Odds Ratio (95% CI)* Odds Ratio (95% CI)* 
Q1 1.00 1.00 
Q2 0.76 (0.39 -1.48) 0.82 (0.41-1.58) 
Q3 0.55 (0.27-1.09) 0.57 (0.28-1.16) 
Q4 0.61 (0.31-1.23) 0.56 (0.27-1.16) 
Q5 0.50 (0.23-1.10) 0.40 (0.18-0.88) 
P for trend 0.063 0.014# 
 
*On top of covariates listed at the bottom of Table 2.4, this analysis also 
adjusted for ER-alpha activity and free estradiol.  
# indicates P value <0.05. 
 
 
We also performed further analysis by including both free estradiol 
and ERα-mediated estrogenic activity as covariates in the same model to 
check if there was significant confounding effect between these two factors 
(Table 2.5). The results showed that the risk estimates of hip fracture 
associated with these two factors across quintile levels remained essentially 
the same.  
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Figure 2.5: Associations between free estradiol and ERα-mediated 
estrogenic activity and hip fracture risk  
 
Low-Q1-Q2, High-Q3-Q5 of serum parameters levels. Women with both low 
Free estradiol and ERα-mediated estrogenic activity are set as the reference 




The positive correlations between ERα-mediated estrogen activity and 
serum free estradiol levels (Pearson’s correlation coefficient=0.253, 
P<0.0001), serum estrone levels (Pearson’s correlation coefficient=0.382, 
P<0.0001) and the sum of the two estrogens (Pearson’s correlation 
coefficient=0.384, P<0.0001) were generally weak. We thus examined the 
joint effects of free estradiol and ERα-mediated estrogenic activity on hip 
fracture risk (Figure 2.5). Since there are currently no biologically or 
clinically defined values of low and high levels for free estradiol or ERα-
mediated estrogenic activity. We grouped the subjects based on the following 
criteria for this analysis. Subjects in the lowest 2 quintiles (Q1-Q2) were 
categorized as women with low level and those in the highest 3 quintiles (Q3-
Q5) were categorized as women with high level (Figure 2.5). This approach 
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was chosen because the difference in risk estimates was greatest between Q2 
and Q3 for both biomarkers. Compared to women in low-level groups for both 
markers, women who were in high-level group for either free estradiol or 
ERα-mediated estrogenic activity had 26% to 32% reduction in hip fracture 
risk, although these risk estimates did not reach statistical significance due to 
small sample size (there were only 26 cases in the category with high level for 
free estradiol but low level for ERα-mediated estrogenic activity, and 28 cases 
in the category with low level for free estradiol but high level for ERα-
mediated estrogenic activity). However, the risk reduction was greatest in 
women who were in high-level groups for both biomarkers. Compared with 
women in the lowest 2 quintiles of both free estradiol and ERα-mediated 
estrogenic activity, women in the highest 3 quintiles for both biomarkers had a 
statistically significant 55% reduction in hip fracture risk (Figure 2.5). The 
interaction term between these two biomarkers was not statistically significant 
(p=0.807), indicating that there was no multiplicative interaction between 





In this study, we found that high levels of free estradiol and ERα-
mediated estrogenic activity in sera were associated with reduced hip fracture 
risk in Chinese postmenopausal women. This reduction was still present after 
adjustment for other known risk factors of hip fracture, including age and BMI. 
To our knowledge this is the first study in an Asian population, and supports 
the contention that higher ERα-mediated estrogenic activity in the sera of 
postmenopausal women may be sufficient to lower hip fracture risk. 
Experimental studies have provided evidence for the bone-stabilizing 
effects mediated by ERα in maintaining bone mineral density (Hertrampf et al. 
2008; Seidlova-Wuttke et al. 2008). Using the cell-based bioassay, we 
encountered the unexpected observation that the correlation between ERα-
mediated estrogenic activity and free estradiol was relatively weak. Initially, 
this might seem surprising since estradiol, being the most potent natural 
estrogen, would be expected to contribute to the bulk of ERα-mediated 
estrogenic activity in sera. However, in post-menopausal women with low free 
estradiol levels, many other compounds discussed above can bind to ERα to 
increase its overall-mediated estrogenic activity and hence reduce hip fracture 
risk. In addition, non-steroidal signaling pathways, including those mediated 
through growth factors and kinases such as the estrogen independent genomic 
pathways, may impact global ERα-mediated estrogenic activity. In support of 
this study, a case control study of breast cancer among post-menopausal 
women in Germany also found low correlation between estradiol and ERα-
mediated estrogenic activity (Widschwendter, et al. 2009). Our results showed 
that both free estradiol and ERα-mediated estrogenic activity appeared to 
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influence hip fracture risk independently, and risk reduction was greatest in 
women who had high levels of both free estradiol and ERα-mediated 
estrogenic activity. The independent effects of these two biomarkers suggest 
that apart from the direct activation of ERα by free estradiol, both biomarkers 
may also act via independent mechanistic pathways in the prevention of 
osteoporotic hip fracture.   
Conversely, free estradiol may also bind to other isoforms of estrogen 
receptors apart from ERα to mediate its protective effect on hip fracture risk. 
In addition to being a potent activator of ERα, estradiol is also a potent 
activator of ERβ, an ER isoform that can be detected in osteoblasts, 
osteoclasts and osteocytes of bone specimens from post-menopausal women, 
albeit at lower levels than ERα (Batra et al. 2003).  Despite the observation 
that mice with deficient ERβ-function (βERKO) have normal trabecular 
architecture, the possibility exists that a specific set of genes important for 
bone metabolism in women may be activated by estradiol binding to ERβ 
(Nilsson and Gustafsson 2011a). Besides transcriptional activation in the 
nucleus of bone cells, estradiol can also regulate bone metabolism through 
membrane bound receptors. Estradiol can activate a G-protein coupled 
receptor homolog (GPR30) or to membrane bound ER resulting in the 
activation of MAP kinase pathways (Kousteni, et al. 2001) to regulate 
apoptosis in osteoclasts and osteoblasts (Kousteni, et al. 2003). In this context, 
a truncated variant of ERα (ERα36) lacking the transactivation domain can be 
activated by picomolar levels of estradiol to regulate bone remodeling. This 
variant ERα36 is reported to be strongly expressed in osteoblasts and 
osteoclasts of postmenopausal women with normal bone density and less so in 
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those with osteoporosis. Using human bone cells in vitro, it was demonstrated 
that ERα36 was able to induce anti-apoptotic signaling on osteoblasts and the 
converse in osteoclasts through ERK1/2 and ROS pathways (Xie et al. 2011).  
Recent studies on Caucasian women showed that estradiol was not 
independently associated with hip fracture risk, notably, the mean BMI among 
the women in Western studies (Chapurlat et al. 2000a; Lee et al. 2008b) were 
higher than that among our leaner, Chinese women. Since high BMI is an 
established strong protective factor for hip fracture (De Laet, et al. 2005), it is 
possible that high BMI may compensate for the influence of low estradiol on 
bone loss in heavier women. Hence, the association between residual estradiol 
levels and hip fracture risk in menopausal women may be more evident in 
leaner Asians. In support of this hypothesis, women with no residual ovarian 
estradiol production due to bilateral oophorectomy after natural menopause 
had increased fracture risk, but this risk was reduced in those who were obese 
(Melton, et al. 2003). 
High SHBG levels have been reported to be a risk factor of subsequent 
hip fracture independent of estradiol and other risk factors (Chapurlat, et al. 
2000b; Lee et al. 2008b). In our study, there was a trend whereby fracture 
cases had higher SHBG, although this did not reach significance. Although 
association of SHBG with hip fracture was significant in the WHI study, risk 
was attenuated after multiple factor adjustment that includes BMI.(Lee, et al. 
2008a) In the EPIDOS study (Chapurlat et al. 2000b) the Relative Hazard 
(RH) of SHBG in relation to hip fracture risk decreased markedly after 
adjustment for body weight from (RH 2·5 [95% CI 1·37–4·61]) to (RH 
1·61[95% CI 0·99–2·62]). Differences between our study and the above may 
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be because our subjects were lighter in weight and were of Chinese ethnic 
origin, or simply due to insufficient sample size. Women with lower weight 
have higher levels of SHBG (Maggio, et al. 2008b; Toscano, et al. 1992) and 
weight is a strong predictor of hip fracture risk.(Armstrong, et al. 2010) 
Interestingly there is a clear ethnic difference in levels of serum estradiol and 
SHBG and comparison of serum hormone levels between British and rural 
Chinese reveals that estradiol was significantly lower and SHBG was 
significantly higher in Chinese postmenopausal women (Wang, et al. 1991). 
Although SHBG was negatively correlated with free E2 in our cohort, it was 
not shown to be an independent risk factor after adjusting for confounders 
using conditional logistic regression analysis.  
Levels of genistein and daidzein were not significantly associated with 
hip fracture risk in this subset of hip fracture cases. Recently we have shown 
that consumption of soy products in foods may was associated with a 21 to 
36% reduction in risk of hip fractures (Koh et al. 2009b). In this subset, 
consumption of soy by cases was not different from controls and this was 
confirmed by measurement of the soy phytoestrogens genistein and diadzein 
in sera. This study was therefore not able to evaluate the effects of soy 
phytoestrogens on hip fracture risk. One possible reason would be that blood 
specimens were not collected after overnight fasting therefore levels of 
genistein and daidzein may not be representative of the individuals diet 
patterns therefore not a good biomarker to predict the hip fracture risk.  
The strengths of our study include the use of a comprehensive 
nationwide hospital database that was able to capture practically all hip 
fracture cases, as Singapore is a small city-state where all such cases are 
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expected to be hospitalized. In addition, the use of questionnaire data and 
blood specimens collected before the occurrence of fracture minimizes recall 
and reverse causality bias. Limitations of this study are that the results are 
based on a blood sample collected at single time point, and the lack of data 
regarding falls, family history of fragility fractures and weight loss. The 
natural fluctuation of estrogens that most likely occurred equally in both cases 
and controls could lead to the underestimation of the true associations between 
the biomarkers measured and the risk of hip fracture. Furthermore, willingness 
to donate blood for research should not influence the estrogen-hip fracture 
associations in this study. Hence, the results obtained from women who gave 
blood prior to fracture in this study would also be applicable to the other group.  
We did not have information on the use of drugs such as thyroid 
hormones, glucocorticoids and proton pump inhibitors, which could affect 
bone density and hip fracture risk in our cohort of elderly women. However, 
the use of such drugs is unlikely to be highly prevalent in population-based 
studies such as ours.  We also did not have data on bone mineral density in our 
study population. However, while osteoporosis is often defined in terms of 
bone mineral density according to WHO guidelines, in the light of recent 
advances on the structural basis of skeletal fragility, it became clear that bone 
density represents only one of the contributors to bone strength. Even if bone 
mineral density is within acceptable range, disruption of bone 
microarchitecture or alteration in the amount and variety of proteins in bone 
can still increase the risk of fractures (Nuti, et al. 2009). Hence, our study of 
hip fracture risk addresses this clinically most important and direct 
consequence of osteoporosis. Finally, the relatively small sample size does not 
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give us sufficient power to detect significant difference in the levels of most of 
the estrogenic biomarkers between cases and controls.  
In conclusion, high levels of free estradiol and ERα-mediated 
estrogenic activity in sera were associated with decreased risk of osteoporotic 
hip fracture, and our data suggest that these two markers might act via 
independent mechanistic pathways in the prevention of osteoporosis. The use 
of these two parameters in combination with other established criteria such 
age, weight,(Armstrong et al. 2010) diabetes,(Koh et al. 2010) smoking, 
physical activity, alcohol intake and corticosteroid use may enhance the 
sensitivity of screens such as the World Health Organization FRAX scoring 
especially for women of Chinese ethnic origin.(Kanis, et al. 2009) This will 
identify a sub-group of women who are at higher risk of hip fracture where 
early management needs to be considered. We acknowledge that estrogen-
independent processes such as oxidative stress have important roles in 
trabecular bone strength (Manolagas 2010), quantitative computed 
tomography shows that cortical bone, unlike trabecular bone, remains stable in 
women until after menopause (Riggs, et al. 2004; Riggs, et al. 2008). It is 
plausible that the low, but supra-threshold, levels of estrogens in menopausal 
women reduces the risk of hip fractures by maintaining the strength of cortical 
bone, which comprises 80% portion of the skeleton (Bonnick and Bonnick 
2009). The evaluation of therapeutic strategies including ultra-low-dose 
estrogen therapy such as a quarter of the regular dose (Prestwood, et al. 2003) 
or selective ER agonists (Marini, et al. 2007) may be warranted to reduce hip 
fracture for women with low serum estrogenicity.  
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CHAPTER 3: ROLE OF ESTROGENIC FACTORS IN 
BREAST CANCER RISK 
The contents of this Chapter are based on the Author’s peer-reviewed 
publication in: Endocr Relat Cancer. 2013 Dec 9. 
(http://www.ncbi.nlm.nih.gov/pubmed/24322303) 	  
 
In the previous study, both high ERα mediated bioactivity and free 
estradiol are independently associated with reduced risk of hip fracture 
indicating that these two estrogenic biomarkers are two different measures of 
estrogenicity. In this chapter, we would like to determine if ERα mediated 
bioactivity is associated with breast cancer risk in the same cohort of 
postmenopausal women. We have also added ERβ bioassay in addition to ERα 
bioassay in this study to examine the role of ERβ mediated bioactivity in 
predicting the risk of breast cancer. 
 
3.1 Introduction 
There exists ample experimental, epidemiologic and clinical evidence 
linking estrogens and breast cancer risk (Henderson and Feigelson 2000; 
Russo and Russo 2006). Several established risk factors for breast cancer have 
been strongly associated with sex hormone levels, suggesting that these 
factors affect the estrogen-signaling pathway to impact breast cancer risk (Key 
et al. 2011). Endogenous hormone levels have been used to estimate breast 
cancer risk in nine previous prospective studies done among postmenopausal 
women (Key, et al. 2002b). A reanalysis of pooled data from of these studies 
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showed that postmenopausal women with relatively high serum concentrations 
of sex hormones such as estradiol and testosterone had a roughly two-fold 
higher risk for breast cancer compared to women with lower levels. Of those 
studies, all but one in Japan (Kabuto, et al. 2000), were conducted in North 
America or Europe where women were known to have higher body mass 
index and also more likely to use hormone replacement therapy. Higher body 
mass index could contribute to higher estrogen levels since adipose tissues are 
a source of estrogen in postmenopausal women (Siiteri 1987).  Furthermore, 
marked differences in circulating estrogen concentrations have been reported 
between Asian and Caucasian women (Bernstein, et al. 1990; Shimizu, et al. 
1990; Wu and Pike 1995).  Conversely, results recently published from the 
multi-ethnic cohort study including Japanese American, White, Native 
Hawaiian, African American, and Latina women also showed that the 
association between sex hormones and breast cancer risk is generalizable to an 
ethnically diverse population (Woolcott, et al. 2010). 
Reproductive factors have also been shown to be associated with risk 
of breast cancer in the Singapore Chinese Health Study (SCHS) Cohort.	   Late 
age at menarche (≥17 years) and increasing number of live births were 
associated with a significant reduction in breast cancer risk. Nulliparity, late 
age at first live birth, family history of breast cancer, daily alcohol drinking, 
late age at menopause, and a high BMI (28+ kg/m2) in postmenopausal 
subjects were positively associated with risk of breast cancer (Koh, et al. 
2003a). This suggests that estrogenic pathways could be involved in the 
pathogenesis of breast cancer. 
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Several studies also investigated the role of phytoestrogens intake on 
breast cancer risk in Asian populations. A meta-analysis of studies 
investigating soy intake and breast cancer risk in Asia or in Asian-Americans 
showed a stepwise reduction in breast cancer risk with increasing soy intake. 
Similarly in the SCHS Cohort, soy intake was associated with a reduced risk 
of breast cancer (Wu, et al. 2008a). Interestingly, serum biomarkers of 
phytoestrogens exposure have been shown to be associated with breast cancer 
in Caucasians. Using LC-MS/MS to measure genistein levels in plasma, it was 
shown to be inversely associated with breast cancer risk in the EPIC study 
OR=0.68, 95%CI 0.47-0.98 (Verheus, et al. 2007b).  
As for breast cancer, both ERα and ERβ bioactivity were shown to be 
independently associated with increased risk in European studies (Fourkala, et 
al. 2012; Widschwendter et al. 2009). Specifically, in a case-control study 
conducted in Germany where blood was collected post-diagnosis, women in 
the highest quintile of both serum ERα and ERβ bioactivities had 
approximately seven times the risk of breast cancer compared to women in 
lower levels of both receptor bioactivities (Widschwendter et al. 2009). More 
recently, in a case-control study nested in a cohort of women in UK, ERα 
bioactivity was shown to be independently associated with breast cancer risk 
in serum collected more than 2 years before diagnosis for breast cancer cases 
(Fourkala et al. 2012). These studies suggest that assays for serum ERα and 
ERβ bioactivity may be useful in the prediction and management of breast 
cancer at a population level as well as at clinical setting.  
Singapore Chinese women are currently experiencing one of the 
highest increase in breast cancer incidence rate in the world. Over the past 35 
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years from 1970 to 2005, incidence rates of breast cancer tripled from 20.0 to 
60.0 per 100,000 (National Registry of Diseases Office 2008). Factors causing 
this rapid rate increase in this historically low-risk population are largely 
unclear. Utilizing prospectively collected sera from women of a population-
based cohort study in Singapore, we investigated the associations between 
levels of estrogens, phytoestrogens and estrogen receptor-mediated bioactivity 
and breast cancer risk among postmenopausal women. Estrogenic compounds 
present in the serum other than estrone and estradiol may activate ERα-










Both cases and controls were identified from the Singapore Chinese 
Health Study, which has been described above in Chapter 2.  
 
Case ascertainment 
Incident breast cancer cases were identified through the population-
based cancer registry in Singapore (Office 2008). As of 28 June 2010, among 
women who were postmenopausal at recruitment, 626 developed breast cancer.  
All cases were further verified by manual checking of pathological and 
medical records. Blood donated prior to cancer diagnosis was available on 169 
incident breast cancer cases for this study. Compared with breast cancer 
patients who did not donate a blood sample, those who donated were younger 
at diagnosis (66.7 versus 64.9 years).  Patients who did not donate blood 
samples were less educated (45.3% had no formal education) than those who 
did (20.7% had no formal education). Those who did not donate biospecimens 
were also more likely to have advanced stage of breast cancer but less likely to 
use hormone replacement compared to those who donated. Otherwise, there 
was no significant difference in body mass index or prevalence of positive 






For each of the 169 cases, up to three control subjects were randomly 
selected among all female cohort participants who had donated blood samples, 
and who were alive and free of breast cancer history at the time of cancer 
diagnosis of their index case. The chosen controls were matched to the index 
case on age at study enrollment (±3 years), dialect group (Hokkien, 
Cantonese), dates of study enrollment (±2 year) and of blood collection (±6 
months). For the 169 cases, there were 19 cases where only one eligible 
control was found for each of them, and 43 cases where only two controls 
were found for each of them.  The other 107 cases had three controls each. 
 
Blood analysis  
 Serum samples were analyzed based on similar methods as the hip 
fracture study. Filtered sera were collected in aliquots for measurements of 
estrone, estradiol, genistein, daidzein and sex hormone binding globulin 
(SHBG) and ERα and ERβ mediated estrogenic activity.  
 Serum SHBG concentrations were quantified by a solid-phase, two-
site chemiluminescent immunoassay using the Immulite Analyzer (Siemens). 
The solid phase is a polystyrene bead with a monoclonal antibody specific for 
SHBG. The intra- assay inter-assay RSD for SHBG in the range of 2-180 nM 
were 6.7% and 2.0%, respectively. The measurement was done in an 
endocrine lab facility in National University of Singapore. Percent free 
estradiol was calculated from serum SHBG levels based on the following 
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regression model: Percent free estradiol=-0.01533 × serum SHBG + 2.921 
(Langley et al. 1985). Free estradiol level for each subject was then computed 
as the product of percent free estradiol and total estradiol level similar to the 
hip fracture study. 
 Biological activity of estrogens in serum was assessed using a 
validated estrogen-driven recombinant cell bioassay (Wong et al. 2007a) 
similar to the hip fracture study.  
 
Statistical analysis 
  The distributions of all biomarkers measured were markedly skewed 
with a long tail toward high values, which were corrected, to a large extent, by 
transforming the original values to logarithmic values. Therefore, formal 
statistical test was performed on logarithmically transformed values, and 
geometric (as opposed to arithmetic) means were presented.  The mixed effect 
model method that takes into account matching was used to examine the 
differences in the concentrations of serum biomarkers between breast cancer 
cases and control subjects with adjustment for other covariates, namely, body 
mass index (<20, 20-<24, 24-<28, and 28+ kg/m2), number of live births 
(none, one to two, three to four, five or more), age at menarche (<13, 13-14, 
15-16, 17+ years), use of hormone replacement (yes, no) and family history of 
breast cancer (yes, no).  
   We used the conditional logistic regression method to examine the 
associations between serum biomarkers measured and risk of breast cancer in 
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our main analysis. For subgroup-analysis involving stratification by receptor 
positivity of breast cancer cases and time between blood draw and diagnosis, 
unconditional logistic regression models that included all the controls in this 
study were used to examine the association between serum biomarkers and 
breast cancer risk. In this study, our aim is to see how estrogen levels and 
bioactivity in cases compared to the controls may affect the risk of breast 
cancer. Hence, study subjects were grouped into quartiles of individual serum 
parameters based on their distributions among control subjects because they 
formed the baseline or comparison group. Furthermore, in the general 
population, since the number of women without breast cancer far outnumbers 
those with breast cancer, the levels in a population are essentially defined by 
the levels in the controls. The magnitude of the association was assessed by 
odds ratio (OR) and its corresponding 95% confidence interval (CI) and P 
value.  Additional analysis also included quartile levels of estrone, free 
estradiol, SHBG and ERα and ERβ-mediated bioactivity in the same model. 
For the unconditional logistic regression analyses, age at blood draw was 
included as a covariate. All analyses were carried out using the SAS version 
9.1 (SAS Institute Inc, Cary, North Carolina). The statistical significance level 











Mean age at blood taken (years)  60.9 (7.2) 60.0 (6.5) 
Body mass index (kg/m2)   
<20 16 (9.5) 45 (10.6) 
20-24 86 (50.9) 246 (57.8) 
24-28 50 (29.6) 109 (25.6) 
28+ 17 (10.1) 26 (6.1) 
Dialect (%)     
   Cantonese 96 (56.8) 249 (58.5) 
   Hokkien 73 (43.2) 177 (41.5) 
Level of education (%)    
    No formal education 35 (20.7) 109 (25.6) 
    Primary school  81 (47.9) 195 (45.8) 
    Secondary and above 53 (31.4) 122 (28.6) 
Age at menarche (years)     
    <13 27 (16.0) 82 (19.3) 
13-14 77 (45.6) 164 (38.5) 
    15-16 52 (30.8) 139 (32.6) 
17+ 13 (7.6) 41 (9.6) 
Number of live births     
None 20 (11.8) 32 (7.5) 
1-2 61 (36.1) 134 (31.5) 
3-4 54 (31.9) 184 (43.2) 
5+ 34 (20.1) 76 (17.8) 
Use of menopausal hormone therapy (%)  18 (10.7) 26 (6.1) 
Soy isoflavones (mg/1000kcal/day)  12.4 (9.2) 13.4 (9.6) 
Family history of breast cancer  4 (2.4) 5 (1.2) 
Note: Figures indicate mean (standard deviation) for continuous data and 
number (percent) for categorical data 
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Among the 169 cases of breast cancer, the mean time interval from 
blood draws to the occurrence of breast cancer was 4.0 years [standard 
deviation (SD) 2.5 years)], and only 43 cases (25%) had blood drawn within 2 
years before cancer diagnosis. The mean age at cancer diagnosis was 64.9 (SD 
7.5; range 48.3-82.0) years. Compared to controls, a higher proportion of 
women with breast cancer had BMI≥24 kg/m2, had secondary school 
education or higher, was nulliparous or had fewer live births, and was older at 
age of first live-birth, had higher intake of soy isoflavones which were 
observations similar to previous results published from this cohort of women 
(Koh, et al. 2003a). Only 6.1% among controls and 10.7% among cases in this 
study were users of hormone replacement (Table 3.1).  
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Table 3.2: Geometric means (95% Confidence Interval) of serum 





2-sided P * 
Estrone (pM)  404.70 (355-461.36) 335.96 (308.28-366.12) 0.021# 
Estradiol (pM)  66.26 (57.26-76.66) 58.82 (53.46-64.74) 0.185 
SHBG (nM) 44.60 (41.32-48.16) 47.62 (45.3-50.08) 0.165 
Free estradiol (pM) 1.38 (1.2-1.6) 1.16 (1.06-1.28) 0.051# 
ERα activity (pM 
estradiol equivalent) 
25.54 (24.66-26.44) 24.40 (23.84-24.96) 0.032 











Daidzein (pM) 6587.4 (4858.4-8931.8) 7259.3(5850.74-9007.1) 0.532 
  
  * Test was using general linear model that retained the matched case-control 
sets with adjustment for body mass index, number of live births, age at 
menarche, use of hormone replacement and family history of breast cancer. 




Breast cancer cases tended to have raised circulating serum levels of estrone, 
estradiol, free estradiol, ERα- and ERβ-mediated estrogenic activity, but lower 
serum SHBG levels, genistein and daidzein levels than controls, although only 
the differences for estrone, free estradiol and ERα-mediated estrogenic 
activity levels reached statistical significance (Table 3.2).
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Table 3.3.1: Serum estrogenic parameters and risk of postmenopausal 
breast cancer. 
 
Biomarker Range Cases Controls OR (95% CI)a OR (95% CI)b 
Estrone      
Q1 23.65-205.5 37 106 1.00 1.00 
Q2 207.5-284.0 33 106 0.87 (0.49-1.54) 0.83 (0.45-1.51) 
Q3 285.5-455.5 39 107 1.10 (0.63-1.92) 0.90 (0.49-1.66) 
Q4 ≥457.5 60 105 1.60 (0.94-2.72) 1.32 (0.63-2.75) 
P for trend    0.05# 0.54 
      
Estradiol      
Q1 4.365-34.3 33 106 1.00 1.00 
Q2 34.4-50.25 42 107 1.15 (0.64-2.06) 1.01 (0.54-1.89) 
Q3 50.35-76.6 47 105 1.43 (0.80-2.54) 1.17 (0.61-2.26) 
Q4 ≥76.95 47 106 1.33 (0.75-2.36) 0.78 (0.37-1.66) 
P for trend    0.26 0.60 
      
SHBG      
Q1 8.39-33.5 55 106 1.00 1.00 
Q2 33.7-47.4 34 106 0.65 (0.38-1.11) 0.72 (0.41-1.24) 
Q3 47.5-67.53 46 106 0.80 (0.47-1.34) 0.94 (0.55-1.61) 
Q4 ≥68.1 34 106 0.65 (0.37-1.12) 0.74 (0.41-1.34) 
P for trend    0.20 0.52 
      
Free estradiol     
Q1 0.065-0.668 30 106 1.00 1.00 
Q2 0.673-1.04 42 106 1.29 (0.73-2.30) 1.07 (0.58-1.96) 
Q3 1.045-1.661 51 106 1.72 (0.97-3.03) 1.37 (0.74-2.54) 
Q4 ≥1.666 46 106 1.47 (0.83-2.61) 0.78 (0.37-1.63) 
P for trend    0.13 0.77 
      
ERα activity     
Q1 12.39-21.01 26 107 1.00 1.00 
Q2 21.03-23.63 38 106 1.45 (0.79-2.64) 1.30 (0.69-2.45) 
Q3 23.66-26.64 41 106 1.60 (0.88-2.92) 1.44 (0.74-2.81) 
Q4 ≥26.65 64 106 2.59 (1.44-4.65) 2.39 (1.17-4.88) 
P for trend    0.001# 0.016# 
      
ERβ activity     
Q1 11.03-20.16 37 104 1.00 1.00 
Q2 20.22-24.46 40 104 1.01 (0.56-1.84) 0.99 (0.54-1.82) 
Q3 24.47-27.48 33 104 0.96 (0.47-1.95) 0.94 (0.46-1.94) 
Q4 ≥27.51 54 104 1.53 (0.77-3.04) 1.41 (0.69-2.88) 
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Table 3.3.2: Serum phytoestrogen levels and risk of postmenopausal 
breast cancer  
 
Biomarker Range Cases Controls OR (95% CI)a 
Genistein     
Q1 79.10-11750 52 124 1.00 
Q2 11800-46050 47 123 0.94 (0.57-1.56) 
Q3 47000-147500 53 123 1.07 (0.65-1.78) 
Q4 ≥150500 42 123 0.81 (0.48-1.35) 
P for trend    0.419 
Diadzein     
Q1 8.86-1540 45 124 1.00 
Q2 1595-7165 52 123 1.15 (0.71-1.89) 
Q3 7225-26000 50 123 1.12 (0.68-1.85) 
Q4 ≥26100 47 123 1.05 (0.63-1.73) 
P for trend    0.896 
 
a Adjusted for body mass index (<20, 20-<24, 24-<28, and 28+ kg/m2), 
number of live births (none, one to two, three to four, five or more), age at 
menarche (<13, 13-14, 15-16, 17+ years), use of hormone replacement (yes, 
no) and family history of breast cancer (yes, no). 
b Adjusted for covariates in model 1 and also quartile values of serum estrone, 
free estradiol or total estradiol (for SHBG), SHBG, ERα activity and ERβ 
activity. 




Using multivariate logistic regression, adjusting for known and 
measured confounders, we observed borderline dose-dependent activity for 
estrone which exhibited a 60% increase in risk for women in the highest 
quartile relative to those in quartile one (Table 3.3.1). There were no clear 
dose-dependent associations between serum total estradiol, free estradiol, 
SHBG and ERβ-mediated activity, genistein and daidzein levels (Table 3.3.2) 
and risk of breast cancer. Interestingly, compared to women in the lowest 
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quartile, ERα-mediated bioactivity was associated with a dose-dependent 
increase in breast cancer risk from a 45% higher risk in quartile two to 159% 
higher risk in the highest quartile (Table 3.3.1).  Reanalysis done with 
minimal value of LOD (20pM) assigned to five missing values of ERβ 
showed essentially the same results; there was no significant association 
between serum ERβ levels and breast cancer risk. 
To examine the independent associations of individual measured 
estrogenic factors on breast cancer risk, further adjustments for estrone, free 
estradiol, SHBG, and ERα- and ERβ-mediated bioactivity were performed 
(Table 3.3.1, last column). After adjusting for ERα-mediated activity, the 
dose-dependent relationship between estrone and breast cancer risk was no 
longer evident; the ORs (95% CI) for those in quartiles 2, 3 and 4 were 0.80 
(0.45-1.42), 0.88 (0.49-1.57) and 1.08 (0.58-1.99), respectively (p for 
trend=0.74), suggesting that ERα-mediated bioactivity was primarily 
responsible for the effect of estrone on breast cancer risk. Additional 
adjustment for free estradiol, SHBG and ERβ bioactivity did not materially 
change the risk estimates, as can be seen from Table 3.3.1.  In contrast, even 
after adjusting for estrone, free estradiol levels, SHBG and ERβ bioactivity, 
the strong association with ERα-mediated activity was essentially unaltered 
with a 2.4-fold increase (OR = 2.39; 95% CI 1.17-4.88; p=0.016) in breast 
cancer risk (Table 3.3.1).  
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Table 3.4:  Serum ERα-mediated bioactivity and risk of postmenopausal 
breast cancer according to ER status of cancer cases. 
Biomarker  Cases Controls OR (95% CI)* 
ER positive cancer 
ERα activity    
Q1  11 107 1.00 
Q2  17 106 1.46 (0.63-3.35) 
Q3  13 106 0.95 (0.39-2.34) 
Q4  28 106 2.43 (1.00-5.94) 
P for trend   0.10 
     
ER negative cancer 
ERα activity    
Q1  5 107 1.00 
Q2  7 106 2.28 (0.66-7.88) 
Q3  9 106 3.26 (0.97-10.95) 
Q4  9 106 3.63 (1.01-13.08) 
P for trend   0.04# 
 
ER unknown cancer  
ERα activity    
Q1  10 107 1.00 
Q2  14 106 1.27 (0.53-3.07) 
Q3  19 106 1.56 (0.66-3.70) 
Q4  27 106 1.71 (0.70-4.20) 
P for trend   0.21 
 
*Adjusted for body mass index (<20, 20-<24, 24-<28, and 28+ kg/m2), 
number of live births (none, one to two, three to four, five or more), age at 
menarche (<13, 13-14, 15-16, 17+ years), use of hormone replacement (yes, 
no), family history of breast cancer (yes, no) and quartile value of estrone and 
free estradiol levels. 
# indicates P value <0.05. 
OR: odds ratio; CI: confidence interval.  
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To further delineate the role of serum ERα bioactivity, we also 
performed an analysis to compare risk in ERα-positive or ERα-negative 
tumors. ER receptor status was available for 58.6% of breast cancer cases. 
There were 69 ERα-positive and 30 ERα-negative breast cancer diagnoses.  
Compared to the lowest quartile, the ORs (95% CI) for women in the 
highest quartile were statistically significant at 2.43 (1.00-5.94) for ER 
positive breast cancer and 3.63 (1.01-13.08) for ER negative breast cancer 
(Table 3.4), suggesting that the positive association between ERα-mediated 
activity and breast cancer risk remained present in both subtypes of breast 
cancer. 
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Table 3.5:  Serum ERα-mediated bioactivity and risk of postmenopausal 
breast cancer according to time between blood draw and cancer diagnosis 
for cases. 
 
Biomarker  Cases Controls OR (95% CI)* 
Within 2 years from blood draw to cancer diagnosis 
ERα activity    
Q1  8 107 1.00 
Q2  4 106 0.57 (0.16-2.02) 
Q3  11 106 1.46 (0.53-4.03) 
Q4  20 106 2.67 (0.94-7.54) 
P for trend   0.02# 
More than 2 years from blood draw to cancer diagnosis 
ERα activity    
Q1  18 107 1.00 
Q2  34 106 1.83 (0.95-3.50) 
Q3  30 106 1.48 (0.75-2.91) 
Q4  44 106 2.15 (1.07-4.33) 
P for trend    0.08 
 
*Adjusted for body mass index (<20, 20-<24, 24-<28, and 28+ kg/m2), 
number of live births (none, one to two, three to four, five or more), age at 
menarche (<13, 13-14, 15-16, 17+ years), use of hormone replacement (yes, 
no), family history of breast cancer (yes, no) and quartile value of estrone and 
free estradiol levels. 




Finally, we examined the association between ERα-mediated activity 
and breast cancer risk by proximity of blood draw to cancer diagnosis. Risk 
estimates obtained from analysis of cases with blood drawn within two years 
prior to cancer diagnosis were essentially similar to the estimates from 
analysis of cases with blood drawn two years or more. Although the p for 
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trend was of borderline statistical significance (p=0.08) for the analysis 
limited to cases with blood drawn more than 2 years from cancer diagnosis, 
relative to the lowest quartile, women in the highest quartile in this group still 
had significantly increased breast cancer risk (OR = 2.15, 95% CI 1.07-4.33) 
(Table 3.5).   
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3.4 Discussion 
 To the best of our knowledge, our study is the first one examining the 
role of estrogens and ERα- and ERβ- mediated bioactivity in the risk breast 
cancer among Chinese postmenopausal women. Our key finding was that 
higher levels of ERα-mediated estrogenic activity in sera were associated with 
increased risk of cancer, and that estrogens, especially estrone, influenced 
cancer risk via interaction with ERα in the pathogenesis of postmenopausal 
breast cancer.  
 Compared to controls, geometric means of total free estradiol, estrone 
and ERα activity levels were significantly higher in pre-disease serum of 
breast cancer cases. After categorizing the biomarker levels into quartiles and 
examining its association with breast cancer risk, we observed a borderline 
dose-dependent relationship, with the highest quartile of estrone exhibiting 
60% higher risk of breast cancer. The association of high estradiol levels with 
higher risk of breast cancer in postmenopausal women is well established 
(Baglietto, et al. 2010; Eliassen, et al. 2006; Farhat, et al. 2011; Kaaks, et al. 
2005; Kabuto et al. 2000; Key, et al. 2003; Manjer, et al. 2003; Missmer, et al. 
2004; Zeleniuch-Jacquotte, et al. 2004). However, the role of estrone in breast 
cancer carcinogenesis is less well appreciated. Some evidence suggests that 
estrone levels, but not estradiol, can be higher depending on lifestyle factors. 
For example, Japanese women born in USA have mean estrone levels higher 
than Caucasian counterparts, contrasting with the largely similar mean 
estradiol levels between these two populations (Probst-Hensch, et al. 2000). In 
the same study, investigators also found differences in estrone levels, after 
accounting for age, weight and androstenedione levels.  On the other hand, 
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Japanese women living in rural areas were found to have 43% lower estrone 
levels compared to weight and age-matched Caucasian women living in 
California (Wu & Pike, 1995), suggesting that the transition from a rural to 
urban lifestyle may have a contributory effect on high estrone levels.  
 Another lifestyle factor may be shift work, as women working 
graveyard night shifts (such as nurses) have been reported to have 
significantly higher estrone levels (20 versus 11.5pg/ml) compared to those 
that never worked night shifts (Nagata, et al. 2008). Although estrone has 20 
to 80% of the bioactivity of estradiol depending on which assay was utilised 
(Fang, et al. 2000), its higher levels indicates that its contribution to overall 
estrogenicity and breast cancer risk is significant in the post-menopausal 
condition in our cohort. The current challenge is to define the role of lifestyle 
modifications that may lower estrone levels and risk of breast cancer. 
 In our study, after we adjusted for ERα activity, the association of estrone 
levels with breast cancer risk was no longer statistically significant; therefore 
we may deduce that the effect of estrone in the pathogenesis of 
postmenopausal breast cancer could be mediated via its binding to ERα. 
 Conversely, we found that ERα-mediated bioactivity appeared to be an 
independent risk factor for breast cancer risk. Logistic regression analyses 
indicated that even after adjustment for known factors of estrogenic action 
such as estradiol, estrone and BMI, women whose ERα-mediated bioactivity 
was in the highest quartile still had significantly higher breast cancer risk 
compared to women in the lowest quartile, suggesting that other factor(s), 
besides estrone and estradiol, was acting via the ERα-mediated genomic 
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signaling systems to increase breast cancer risk. This dose dependent increase 
in risk with high ERα-mediated bioactivity was evident for periods before 4 
years and within 2 years of blood draw, indicating the robustness of the 
association.  
 To our knowledge, this is also the first study to use mammalian cell 
based bioassays to examine prospectively the relationship between ERα-
mediated bioactivity and breast cancer risk. A recent study utilised a yeast-
based reporter gene assay system, and did not observe any overall 
relationships between receptor bioactivity and breast cancer risk among their 
study cohort from the UK (Fourkala et al. 2012). In this study, the association 
between ERα-mediated bioactivity and breast cancer risk was only present in 
the subset of cases whose blood was collected more than 2 years before cancer 
diagnosis (Fourkala et al. 2012). These findings are opposed to those from 
another case-control study that the same group of investigators conducted 
using blood collected from cases in a German population after clinical 
diagnosis, which showed a strong association between ERα bioactivity and 
cancer risk (Widschwendter et al. 2009). Differences between our study and 
that of the UK group could first be due to our use of mammalian cells, which 
are more physiologically relevant in differentiating between agonist and 
antagonist compared to yeast cell-based bioassays used by other investigators 
(Fourkala et al. 2012; Widschwendter et al. 2009). In addition, the 
coregulators involved in transactivation of estrogen sensitive reporter genes 
has been reported to be differ between yeast and mammalian systems (Kohno, 
et al. 1994).  
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 Many other compounds in the serum are also known to be capable of 
binding to ERα and activating the receptor other than the two most abundant 
estrogens present in the blood namely estradiol and estrone. These include 
estrogen metabolites from birth control pills and endocrine disrupting 
compounds (EDCs) that have estrogenic activity. Such estrogenic compounds 
that are present in trace concentrations in the blood can exert biological effects 
and have the potential to provoke synergistic effects at low doses, even at no 
observed effect levels individually (Diamanti-Kandarakis et al. 2009; 
Kandaraki, et al. 2011b). Thus, ERα-mediated estrogenic activity could be a 
more comprehensive and accurate measurement of the combined effects of all 
known and unknown estrogenic compounds present in the sera of women, all 
of which could potentially have an effect on breast cancer risk. Some of these 
ligands of estrogen receptors have been shown to be associated with breast 
cancer risk. For example, higher soy intake that leads to higher levels of 
phytoestrogens in the blood has been shown to be associated with reduced risk 
of breast cancer (Iwasaki, et al. 2008b; Wu et al. 2008a). Similarly, higher 
levels of estrogenic metabolites such as 2-hydroxy estrone that can inhibit 
estrogen receptor activity are also associated with reduced risk of breast 
cancer (Fuhrman, et al. 2012). Thus, ERα- mediated estrogenic activity could 
be a more comprehensive measurement of the combined effects of all known 
and unknown estrogenic compounds present in the sera of women, all of 
which could affect breast cancer risk. Our data indicates that the risk due to 
increased ERα-mediated bioactivity was independent of endogenous estrogens, 
supporting the hypothesis that environmental factors may contribute to breast 
cancer risk in our cohort. Further research is warranted to identify these 
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specific endocrine-disrupting compounds. This increase in exposure to 
potentially carcinogenic environmental factors may be congruent with the 
rapid increase in breast cancer rates in rapidly modernizing Singapore.  
 While the UK study only included ER-positive cases (Fourkala et al. 
2012), we decided to include the investigation of both ER-positive and ER-
negative breast cancer cases in our study. ERα-mediated bioactivity was 
associated with increased risk for both subtypes of breast cancer, suggesting 
that estrogenic activity also promotes the proliferation of ER negative breast 
cancer. Unexpectedly, breast cancer risk was highest among patients with 
ERα-negative tumors, rising to 15-fold higher risk within the highest quartile 
of ERα-bioactivity, suggesting that compounds that were activating ERα-
genomic signaling cascade were also capable of activating other estrogenic 
signaling pathways in breast cancer tissues with absent or significantly lower 
levels of ERα. Several prior studies have showed that oophorectomy (removal 
of ovaries) prevented the formation of both ERα -positive and ERα -negative 
breast cancers. Therefore this suggests that estrogen-driven pathways could 
also play a role in the development of ER-negative breast cancer (1992). 
Accordingly we hypothesize that our mammalian reporter gene assay has 
reflected the presence of estrogenic compounds in the serum of ERα-negative 
breast cancer patients that may activate estrogen signaling in the absence of 
intact ERα. One example is membrane-bound ERα 36, a truncated estrogen 
sensitive receptor present in ER-negative breast cancer, which can mediate 
nongenomic estrogen signaling in the carcinogenesis of ER-negative tumors 
(Rao, et al. 2011).  
  81	  
 Although our data was suggestive of a 1.5 times increase in risk of 
breast cancer for women in the highest quartile level, the association between 
ERβ bioactivity and breast cancer risk did not reach statistical significance and 
was weaker than the association with ERα bioactivity. The role of ERβ in 
breast cancer is debatable. Breast cancer patients who are treated with 
tamoxifen and have high expression levels of ERβ were found to have better 
response and longer survival time (Esslimani-Sahla, et al. 2004; Hopp, et al. 
2004). On the other hand, in ERα -negative breast cancer, high ERβ 
expression is positively correlated with poor prognostic phenotypes (Skliris, et 
al. 2006). Some of these ligands with preferential binding to ERβ have been 
shown to be associated with decreased breast cancer risk. For example, 
genistein is a soy phytoestrogen possessing a high affinity for ERβ (Lee, et al. 
2004), and higher soy intake has been shown to be associated with reduced 
risk of breast cancer (Iwasaki, et al. 2008c; Wu, et al. 2008b). However the 
measurement of phytoestrogens genistein and daidzein levels in our study was 
not shown to be significantly associated with risk of breast cancer. 
 A notable strength of our study is the nesting of the study within a 
population-based prospective cohort that provides the use of questionnaire 
data and blood specimens collected before the occurrence of breast cancer to 
reduce recall and reverse causality bias. Additionally, cancer cases were 
identified using a comprehensive nationwide cancer registry, reducing 
selection bias. However, this study is not without limitations, including the 
fact that our results are based on a blood sample collected at single time point; 
the natural fluctuations of biomarkers that most likely occurred equally in both 
cases and controls could lead to the underestimation of the true associations 
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with breast cancer risk. In this cohort, among postmenopausal women who 
gave blood for research, we limited the selection of cases to women who 
donated blood prior to the occurrence of breast cancer. Matching or statistical 
adjustment in our analyses accounted for the differences in baseline 
characteristics such as age and use of hormone replacement between breast 
cancer cases included and those excluded in this study. Furthermore, 
willingness to donate blood for research should not influence the biomarker-
breast cancer associations in this study. In addition, we acknowledge that the 
presence of existing occult tumors could play a role in the association between 
ERα mediated bioactivity and breast cancer risk in this group of patients with 
a average period of follow up of 4 years. Finally, the relatively small sample 
size, especially when we performed subgroup analyses by estrogen receptor 
positivity, was not able to provide sufficient power to detect significant 
difference in the levels of most of the blood parameters between cases and 
controls.  
  In conclusion, ERα-mediated estrogenic activity in sera was associated 
with significantly increased risk of postmenopausal breast cancer 
independently of estrone levels. There is potential for the development of this 
serum biomarker in postmenopausal women to be developed into a clinical 
index for the prediction of breast cancer risk or to monitor breast cancer 
patients on chemotherapy. 
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Chapter 4: Role of Estrogenic Factors and Lung Cancer 
Survival 
The contents of this Chapter is based on a manuscript which is currently 
under peer-review at Clinical Cancer Research. 
 
The previous two chapters have looked at the role of estrogenic factors 
and risk of hip fracture and breast cancer where estrogen levels in association 
with these diseases have been well studied. In this chapter, we would like to 
investigate the role of estrogenic factors in lung cancer where the role of 
estrogens in the risk and progression of lung cancer is controversial. As the 
number of lung cancer cases in the original SCHS cohort is very small, we 
investigated the association in a hospital based case control study of lung 
cancer in women.  To avoid the issue of reverse causation, and given that the 
majority of these lung cancer patients were in stage 4 disease, we decided to 
look at the role of estrogenic biomarkers and lung cancer survival instead of 
risk of lung cancer in these women. 
 
4.1 Introduction 
Lung cancer is reportedly the most prevalent type of cancer, charting 
as one of the highest cancer-related mortality rate worldwide, coupled with an 
alarmingly low survival rate of 16% reported in one of the studies (E.Olivio-
Marston, et al. 2010; Miki, et al. 2011b). 
  84	  
Lung cancer is broadly classified as small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). The distinction between the two major 
groups is that SCLC spreads more aggressively as compared to NSCLC. 
NSCLC can then be further classified under varied subtypes; adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma. 
The principal cause of lung cancer has been extensively investigated 
and is now recognized to be due to smoking. It is reported that smokers are 22 
times as likely to die of smoking-related cancer than non-smokers (1989). 
However, the increasing incidence of female never-smokers reported with 
lung cancer is becoming an intriguing concern (Marquez-Garban, et al. 2007; 
Seow, et al. 2000) and has disputed the long-term belief that only smokers are 
exposed to the high risk of lung cancer. Furthermore, results of 
epidemiological studies suggest that, among nonsmokers, women have higher 
risk of lung cancer as compared to men(Freedman, et al. 2008; Wakelee, et al. 
2007).  
It was first observed by Taioli and Wynder that there is an association 
between hormonal factors and non-smoking lung cancer. They also reported 
an increase risk with use of hormone replacement therapy (Taioli and Wynder 
1994b). Many studies have therefore attempted to account for the increased 
high lung cancer risk in non-smoking females and concluded that a possible 
reason is due to sexual hormones, particularly estrogens (E.Olivio-Marston et 
al. 2010; Fasco, et al. 2002; Zhao, et al. 2011a). Several studies have thus 
looked into reproductive and hormonal factors and lung cancer risk in women. 
For example, results from studies investigating Hormone Replacement 
Therapy and lung cancer risk are conflicting; some show an elevation in risk 
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(Liu, et al. 2005; Taioli and Wynder 1994a), some show no effect (Elliott and 
Hannaford 2006; Kabat, et al. 2007) whereas others show a reduction in risk 
(Chen, et al. 2007; Schwartz, et al. 2007). Findings from Singaporean Chinese 
women showed that increasing parity was associated with a reduction in lung 
cancer risk (Seow, et al. 2009; Seow, et al. 2002). In support of this, a study 
from Shanghai showed that higher parity, longer length of reproductive period 
and later age of menopause was also associated with reduction in risk (Weiss, 
et al. 2008). These studies suggest a role of estrogens in lung cancer risk. 
In addition, several prospective studies have also shown gender-
disposition for the different histological types of lung cancer. It was reported 
that men are more prone to squamous cell carcinoma with reported incidence 
of 44% cases seen in males, 25% cases in females, whereas females have 
more reported cases of adenocarcinoma subtypes, 28 % in males, 42% in 
females (Zhao et al. 2011a). 
In terms of the role of estrogens in lung cancer progression, a recent 
study that measured estrogen levels in NSCLC patients showed that male and 
female lung cancer patients in the highest tertile of serum estrogen levels have 
worst survival compared to the lowest tertile (Olivo-Marston, et al. 2010b). 
However, population studies investigating the role of ERβ expression in lung 
tumors to predict survival of lung cancer patients have been inconsistent. A 
study done in Japan showed that the absence of ERβ expression is associated 
with poorer prognosis in NSCLC patients (Kawai, et al. 2005). Furthermore a 
study from USA found that men who have tumors with higher ERβ expression 
had lower mortality but it was not seen in women (Schwartz, et al. 2005). On 
the other hand, higher expression of ERβ together with aromatase predicts 
  86	  
worse survival in NSCLC patients(Mah, et al. 2011). In support of this, Stabile, 
et al (2011) showed that high cytoplasmic ERβ expression correlates 
independently with worse survival in lung cancer patients. The role of 
estrogens in the progression of lung cancer in women is still controversial and 
there is lack of research investigating estrogen levels, estrogen receptors 
mediated bioactivity and lung cancer survival in postmenopausal Asian 
women.  
In vitro and in vivo studies have shown that estrogen stimulates the 
growth of lung cancer cells and antiestrogens block its effect (Hammoud, et al. 
2008; Stabile, et al. 2002). Higher ERβ expression levels in NSCLC cell lines 
have also been shown to promote tumor progression (Zhao, et al. 2011b). 
These evidences provide support that estrogens could possibly stimulate lung 
cancer cell growth through estrogen receptors. 
Mechanisms of actions of estrogens on lung cancer cells include acting 
directly as carcinogens through metabolism to catechol estrogens and the 
formation of DNA adducts or as tumor promoters through receptor mediated 
pathways (Stabile et al. 2002). For example, estrogen receptors when bound 
by a ligand alters transcription by binding to estrogen-response element or to 
other transcription factors in the promoter regions of target genes. Conversely, 
estrogen receptors could have other non-genomic effects by associating with 
other growth factor receptors present in the membrane thereby activating 
signaling pathways that promote tumor growth (Levin 2005; Song and Santen 
2006).  
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ERβ is the major estrogen receptor subtype present in lung cancer 
tissues but several studies have debated the presence of ERα because it is 
present either in low levels or in truncated forms. The controversies regarding 
the expression of ERα and ERβ in lung cancer tissues is due to the different 
antibodies and methods employed in immunohistochemistry of cancer tissues 
(Miki, et al. 2011a).  
In this study we aimed to determine the contribution of serum 
estrogenicity to lung cancer survival in postmenopausal Chinese lung cancer 
patients by measuring serum levels of the two endogenous estrogens; estrone 
(E1) and estradiol (E2), the soy phytoestrogens (genistein and daidzein) and 
summated estrogenicity in sera using ERα and ERβ mediated bioactivity by 




Blood samples for this analysis were obtained from cases in a hospital-
based case–control study that was conducted from February 2005 to January 
2008 in the 5 major public-sector hospitals in Singapore. Eligible cases were 
Chinese women with a diagnosis of primary lung carcinoma (all histological 
types). The detailed methodology has been previously described (Tang, et al. 
2010). 
A total of 497 lung cancer patients were identified in the 5 hospitals. 
We excluded 14 cases who did not satisfy the eligibility criteria, and 9 others 
who were not contactable for a variety of reasons (e.g., some were too ill), 
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leaving 474 women. Of these, 401 (84.6%) consented to the interview. 
Histological or cytological reports were reviewed and confirmed the diagnosis 
of primary lung carcinoma in 372 of these women; we excluded 2 patients 
who were subsequently confirmed to have metastatic cancer to the lung. 
Twenty-nine cases were confirmed on the basis of radiological investigations, 
in which metastatic cancer to the lung from other sites was deemed to be 
unlikely on clinical grounds. In total, we had 399 confirmed lung cancer cases 
in this study.  
Trained interviewers administered face-to-face a structured 
questionnaire which elicited a detailed reproductive history, including parity, 
age at birth of first child, usual menstrual cycle length, age of menarche and 
where relevant, menopause and exogenous reproductive hormone use (as 
hormone replacement therapy or oral contraception). Among post-menopausal 
women, the reproductive period was measured as the time period between 
menarche and menopause. Participants’ demographic characteristics, 
occupational history, smoking history, family history of cancer, personal 
medical history, diet, medication used and indoor environmental exposures 
were also obtained. None of the interviews were conducted solely with the 
next-of-kin, although relatives, if present, were allowed to give information 
that was corroborated by the subject. Blood samples were obtained where 
consent was given. The study protocol was approved by the National 
University of Singapore Institutional Review Board and the Ethics 
Committees of the participating healthcare institutions. 
Among 399 cases, 335 were postmenopausal and only 222 agreed to 
donate blood and used for this study. There were no significant differences in 
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baseline characteristics between women who donate blood compared to those 
who did not. At the end of the recruitment period in January 2008, research 
nurses reviewed the case notes of all cases and recorded the date of death from 
when the participant had died. 
 
Blood analysis 
Serum samples were analyzed similar to the breast cancer study.  
Filtered sera were collected in aliquots for measurements of estrone, estradiol, 
gensitein, daidzein, sex hormone binding globulin (SHBG), ERα and ERβ 
mediated estrogenic activity. 45 serum samples have ERβ bioactivity values 
below detection limit and were assigned the value of limit of detection (20pM). 
Statistical analysis 
Data analyses were performed using Stata v.10 (StataCorp 2007; 
College Station, TX) software. The probabilities of overall survival were 
calculated using the Kaplan Meier method and compared using the log-rank 
test. For determination of factors related to overall survival, a Cox 
proportional hazard model was used. The models were adjusted for potential 
confounding variables including age at diagnosis, stage of tumor, smoking 
status, body mass index, histology and time between interview and diagnosis. 
These analyses yielded hazard ratios and their 95% confidence intervals and P 
values. Values of p<0.05 were considered statistically significant. 
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4.3 Results 
 
Table 4.1: Characteristics of 222 postmenopausal Chinese lung cancer 
patients  
Variables n* (%) 
Age at blood taken [years, mean(SD)] 68.7 (9.62) 
Body mass index [kg/m2, mean(SD)] 22.19 (3.85) 
Smoking status  
   Non-smokers 137 (61.71) 
   Smokers 85 (38.29) 
     Smoking duration [years, mean(SD)] 40.52 (19.76) 
Country of birth  
   Singapore 152 (68.47) 
   Malaysia 30 (13.51) 
   China 30 (13.51) 
   Other 10 (14.50) 
Use of hormone therapy  
   Never used 166 (74.77) 
   ≤ 5years 45 (20.27) 
   >5 years 11 (4.95) 
Histology  
   Adenocarcinoma 135 (60.81) 
   Squamous cell carcinoma 15 (6.76) 
   Small cell carcinoma 11 (4.95) 
   Other histological subtypes 41 (18.47) 
   No histology available/cannot be classified 20 (9.01 ) 
Stage at diagnosis  
   Stage 1 13 (5.86) 
   Stage 2 10 (4.50) 
   Stage 3 34 (15.32) 
   Stage 4 127 (57.21) 
Vital Status  
Alive 1(0.45) 
Dead 221(99.55) 
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 All cases with lung cancer were of Chinese ethnic origin.  The mean 
age of diagnosis and blood draw was 68.7 years (Table 4.1). The majority 
(74.8%) had never used any form of hormone replacement therapy. Most 
cases were born and domicile in Singapore (68.5%) and were non-smokers 
(61.7%). Amongst those who smoke (38.3%), the average duration of smoking 
was 40.5 years. Among cases, 60.8% had a diagnosis of adenocarcinoma and 
the majority (72.5%) was diagnosed in late stages 3 and 4. 
Table 4.2: Univariate analysis of risk of death in postmenopausal lung 
cancer patients 
# indicates P value <0.05. 
Factors N HR (95% CI) P-value 
Age(yrs)     
   <60 55 1   
   61-70 62 1.36(0.94-1.97) 0.105 
   71-80 78 2.00(1.40-2.84) <0.0001# 
   >80 27 1.76(1.09-2.83) 0.021# 
BMI (kg/m2)       
<19.6 56 1   
19.6-22.1 55 1.02(0.70-1.49) 0.92 
22.1-25.0 56 0.82(0.56-1.20) 0.30 
>25.0 54 0.84(0.57-1.23) 0.38 
Stage       
   1 13 1   
   2 10 1.25(0.55-2.87) 0.596 
   3 34 1.16(0.61-2.20) 0.645 
   4  127 1.65(0.93-2.94) 0.086 
Smoking       
Non-smokers 137 1   
Smokers 85 1.41 (1.07-1.86) 0.016# 
Histology       
Adenocarcinoma 135 1   
Squamous cell carcinoma 15 0.96 (0.55-1.66) 0.874 
Small cell carcinoma 11 2.75 (1.47-5.16) 0.002# 
Other histological subtypes 41 1.06 (0.74-1.51) 0.754 
No histology available/cannot be classified 20 2.37 (1.44-3.90) 0.001 
Use of Hormone Therapy      
Never used 166 1   
≤ 5years 45 0.82 (0.59-1.14) 0.245 
>5 years 11 0.69 (0.38-1.28) 0.243 
Lag time       
Before diagnosis 109 1   
<=14 days after diagnosis 47 0.82(0.58-1.16) 0.257 
>14 days after diagnosis 66 0.56(0.41-0.77) <0.0001# 




As expected, univariate analysis on lung cancer cases showed that 
older age, higher stage of tumor, and smoking were associated with worse 
survival (Table 4.2). Small cell carcinoma subtype was associated with worse 
survival when compared to adenocarcinoma HR 2.75, 95% CI 1.47-5.16 (p 
value =0.002) (Table 4.2). Furthermore patients whose blood was collected 
greater than 2 weeks after diagnosis were associated with better survival 
compared to patients whose blood was taken before diagnosis of lung cancer. 
These factors were subsequently included in the Cox proportional hazards 
model to determine the effects of serum estrogenicity on lung cancer survival. 
Use of hormone therapy was not associated with survival (Table 4.2). 
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Figure 4.1: Kaplan Meier survival curves for the association of ERβ 





ERβ mediated bioactivity levels are divided into tertiles, (T3 being the highest 




 The overall Kaplan-Meier survival analysis for tertiles of ERβ-
mediated bioactivity is shown in Figure 4.1. Higher ERβ mediated bioactivity 
was dose-dependently associated with worse survival in lung cancer patients 
(p=0.033). Thus at 15 months, the probability of survival was 0.12 at the 






















0 10 20 30 40
Months after Diagnosis
T1 (n=74) T2 (n=74) T3 (n=74)
  94	  
Table 4.3: Multivariate analysis of blood parameters and lung cancer 
survival 
 
Serum Parameters  N Range (pM) HR (95% CI)* 
Estradiol       
T1 74 15.0 to  <41.9 1.00 
T2 73 41.9 to <64.8 1.00 (0.70-1.45) 
T3 73 64.8 to <1000 0.78 (0.51-1.19) 
P for trend     0.262 
Estrone       
T1 74 25.0 to <144 1.00 
T2 73 145 to <302 1.04 (0.72-1.50) 
T3 73 302 to <1000 1.13 (0.77-1.67) 
P for trend     0.542 
SHBG       
T1 74 11.9 to <44.1 1.00 
T2 74 44.1 to <71.1 0.80 (0.54-1.17) 
T3 74 71.7 to <180 0.76 (0.50-1.15) 
P for trend     0.183 
Free Estradiol       
T1 74 0.05 to <0.73 1.00 
T2 73 0.73 to <1.29 1.10 (0.75-1.60) 
T3 73 1.29 to <20.8 0.72 (0.47-1.10) 
P for trend     0.14 
ERα activity       
T1 74 19.5 to <37.7 1.00 
T2 74 37.7 to <53.3 1.39 (0.94-2.07) 
T3 74 53.4 to <193.3 1.06 (0.72-1.57) 
P for trend     0.827 
ERβ activity       
T1 74 5.5 to <38.9 1.00 
T2 74 38.9 to <53.2 1.60 (1.10-2.33) 
T3 74 53.2 to 156.6 1.93 (1.32-2.82) 
P for trend     <0.0001# 
Genistein       
T1 74 250 to <20200 1.00 
T2 74 21100 to <114500 0.96 (0.66-1.40) 
T3 73 119500 to <1145000 0.91 (0.63-1.31) 
P for trend     0.607 
Daidzein       
T1 74 250 to <2595 1.00 
T2 75 2795 to <11300 0.66 (0.45-0.98) 
T3 72 12100 to <204000 0.73 (0.51-1.05) 
P for trend     0.121 
 
*Cox proportional hazards model adjusted for age at diagnosis, stage of tumor, 
smoking status, body mass index, histology, use of hormone therapy and time 
between specimen collection and diagnosis. 
# indicates P value <0.05. 
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Serum estrogen parameters were divided into tertiles to investigate the 
dose-response relationship between these level of compounds/bioactivity and 
lung cancer survival (Table 4.3).  Strikingly, only ERβ mediated bioactivity 
was associated with worse prognosis for lung cancer (p for trend<0.0001). 
Relative to the lowest tertile, patients in the middle and highest tertiles had 
1.60 fold (95%CI 1.10-2.33) and 1.93-fold (95%CI 1.32-2.82) risk of death 
from lung cancer. Remarkably other estrogenic indices like ERα-mediated 
bioactivity, estradiol, estrone, SHBG, free estradiol was not associated with 
survival rate. In particular levels of genistein and diadzein, known to be potent 
activators of ERβ, were not associated with risk of death in this analysis 
(Table 4.3). Since estrone and estradiol can activate both ERα and ERβ 
receptors, we examined the relationships between these natural estrogens and 
receptor bioactivity in sera. Free estradiol was weakly correlated with ERβ 
mediated bioactivity with a Pearson’s correlation coefficient of 0.2873 
(p<0.0001). The correlation between estrone and with ERβ mediated 
bioactivity was weak with a Pearson’s correlation coefficient of 0.1576 
(p<0.0193). ERα mediated bioactivity was moderately correlated with ERβ 
mediated bioactivity with a Pearson’s correlation coefficient of 0.4888 
(p<0.0001). Both genistein and daidzein levels were not correlated with ERα 
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Characteristics of cancer patients between tertiles of ERβ bioactivity 
We examined the differences in baseline characteristics of patients in 
tertiles 1 to 3 (T1-T3) of ERβ mediated bioactivity.  Cases in the highest 
tertile of ERβ bioactivity were younger compared to T1, mean age 68 versus 
70 years. In T2 the mean age was 67 years. Similarly patients in the lowest 
tertile of ERβ bioactivity had lower proportion of hormone therapy users, 13% 
and 12% in T1 and T2 compared to 20% in the highest tertile. When we 
looked at the estradiol levels, as expected cases in the lowest tertile of ERβ 
bioactivity have lowest level of estradiol T1-T3, 66 to 83 to 104 pM.  
However, there is no difference is distribution of stage and histology from T1-
T3 of ERβ bioactivity. In terms of smoking, there are more smokers in the 
lowest tertile of ERβ bioactivity T1 to T3. 
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4.4 Discussion 
 We report the unexpected finding that ERβ, but not ERα, mediated 
bioactivity in sera was associated with poor survival in lung cancer patients. 
Patients whose sera were in the highest tertile of ERβ mediated bioactivity had 
1.93-fold (95%CI 1.32-2.82) risk of death compared to the lowest tertile. 
Although age, smoking, histological subtype and cancer stage were 
significantly correlated with prognosis, the positive association between ERβ 
mediated bioactivity and increased risk of death from lung cancer were 
independent of these factors. Both smokers and non-smokers in highest tertiles 
of ERβ mediated bioactivity had hazard ratios of 1.87 (95% CI, 1.16-3.03) and 
2.03 (95% CI, 0.98-4.18) respectively for lung cancer death. Strikingly related 
estrogenic indices like estradiol, estrone, SHBG, free estradiol and ERα-
mediated bioactivity were not correlated with survival.  
 There is a paucity of studies relating serum estrogens and lung cancer 
survival. One study that we were aware of used an immunoassay that detected 
all the three principal endogenous estrogens (estrone, estradiol and estriol) 
(Olivo-Marston, et al. 2010a). Although no separate analysis was done for 
women, a consistent trend was found wherein higher levels of the total 
endogenous estrogens were associated with poorer survival in early stage lung 
cancers (Olivo-Marston et al. 2010a). Higher aromatase protein expression 
levels, presumably leading to greater production of estrogens from 
aromatization of precursor androgens, also predicted worse survival (Mah, et 
al. 2007). In contrast, the large Women’s Health Initiative randomized 
controlled trial indicates that postmenopausal hormone therapy with 
conjugated equine estrogens alone did not impact on incidence or survival of 
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lung cancer patients (Chlebowski, et al. 2010). Interestingly use of a combined 
estrogen and progestin hormone preparation was associated with more poorly 
differentiated cancers, and cancers with metastatic spread, compared to the 
placebo group (Chlebowski, et al. 2009), indicating that the progesterone 
rather than estrogen effects may be critical. Although estrone, estradiol and 
free estradiol levels were not associated with survival, our data suggest the 
intriguing concept that there may be compounds that preferentially activate 
ERβ that may be contributing to poorer outcomes. Increased mortality was 
most obvious at 15 months where the probability of survival was 0.12 at the 
highest tertile, compared to 0.33 at lowest tertile of ERβ mediated bioactivity. 
 Our finding that ERβ mediated estrogenic activity may worsen 
prognosis in lung cancer is consistent with ERβ being the predominant 
estrogen receptor isoform in lung cancer. Unlike breast cancer where ERα 
positivity is common, immunohistochemistry studies indicate that full length 
ERα protein was not detectable in a majority of lung cancer or normal tissues 
(Raso, et al. 2009). In contrast ERβ protein was expressed in 61% of lung 
cancer and 20% in normal lung samples, and patients with ERβ positive 
tumors had a trend towards increase in mortality (Schwartz et al. 2005). 
Higher ERβ expression also correlated with higher grade of tumors, and when 
coupled with aromatase expression predicted worse survival (Mah et al. 2011). 
The predominant sub-cellular localization of ERβ is the nucleus (Kawai et al. 
2005), where the classic genomic signaling cascade leads to lung cancer cell 
growth and metastasis. Nevertheless cytoplasmic staining of ERβ, albeit to a 
lesser degree than nuclear, have been reported (Stabile et al. 2011). In a recent 
study of 135 lung cancer patients, 60% of lung tumors show strong nuclear 
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ERβ gene expression compared to 29% with strong cytoplasmic expression 
(Song, et al. 2013). Poorer outcomes were also observed in association with 
cytoplasmic ERβ lung tumor expression (Stabile et al. 2011). Ligands specific 
to ERβ, but not ERα, stimulated the proliferation of lung adenocarcinoma cell 
lines. Downregulation of ERβ in lung cancer cells result in poorer response to 
estrogen stimulation when compared with control cells, indicating that ERβ is 
required for estrogen-dependent growth of lung cancer cells. Ligand activated 
ERβ led to rapid activation of cAMP, Akt, and MAPK signaling pathways 
(Zhang, et al. 2009). It is possible that ligands identified by our ERβ bioassay 
can bind to cytoplasmic ERβ to activate such non-genomic pathways to 
promote lung cancer growth (Hershberger, et al. 2009). It has to be noted that 
some studies suggest ERβ negative patients had a significantly worse 
prognosis than ERβ positive (Kawai et al. 2005). Such differences may also be 
related to the differential impact of ERβ expression on clinical outcome by 
disease stage, as early stage lung cancer may be associated with better survival 
compared to poorer survival at later stage lung cancer (Navaratnam, et al. 
2012).  
 Compounds that might contribute to ERα and ERβ mediated bioactivity 
in sera include endogenous estrogens, and exogenous compounds like 
phytoestrogens, pharmaceuticals, pesticides, and industrial chemicals. 
Physiological estrogens such as estradiol, and its bioactive free estradiol 
fraction, can activate both ERα and ERβ receptors. Although both free 
estradiol and estrone correlated weakly with ERβ-mediated bioactivity, 
survival itself was also not associated with either of these estrogens in our 
dataset. Candidate compound(s) that may preferentially activate ERβ in sera 
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include endogenous estrogen metabolites such as 16 alpha-hydroxyestradiol 
(estriol) and other D-ring metabolites that have higher binding affinity to ERβ 
than ERα (Zhu, et al. 2006). Endogenous selective estrogen receptor 
modulators such as the cholesterol metabolite, 27-hydroxycholesterol or other 
oxysterols, might in certain tissue contexts preferentially activate ERβ 
(Umetani, et al. 2007). 
 Phytoestrogens are exogenous compounds known to preferentially 
activate ERβ. In our study the soy isoflavones, genistein and daidzein, did not 
correlate with lung cancer. Neither did these phytoestrogens correlated with 
ERβ mediated bioactivity. However many other phytoestrogen groups such as 
coumestrol; flavones (apigenin); flavonols (kaempferol), flavonone 
(naringenin), chalcone (phloretin) exhibit relative binding affinity that are 
several fold higher for ERβ compared to ERα, depending on the assay used. In 
particular liquiritigenin, a flavone found in Glycyrrhizae uralensis shows a 20-
fold selectivity for ERβ compared to ERα in competitive binding assays 
(Mersereau, et al. 2008). Exogenous endocrine disrupting compounds (EDCs) 
such as 4,49-biphenol may also exhibit higher ERβ activity in transcriptional 
assays (Kuiper, et al. 1998). It has to be noted that EDC compounds having no 
observable effects individually, may in combination activate ERβ signaling 
(Kortenkamp 2007). Furthermore ERβ can also heterodimerise with other 
nuclear receptors like AHR to active target genes giving rise to the possibility 
that ERβ effects observed may be exerted indirectly. In this context, ligands 
for AHR such as dioxins, polycyclic aromatic hydrocarbons (PAHs) or 
halogenated aromatic hydrocarbons (HAHs) may activate ERβ signaling 
through ERβ-AHR cross talk mechanisms (Ohtake, et al. 2009).  
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 Identification of the compounds or groups of compounds that might 
contribute to increase ERβ activity in serum would be important to confirm 
our observations. Although a clear cut recommendation is premature at this 
stage, the effectiveness of anti-estrogens such as tamoxifen (Lother, et al. 
2013) and fulvestrant (Siegfried, et al. 2012) in clinical trials suggest that 
selective blockage of ERβ activity may have a role to enhance lung cancer 
therapy. 
 Remarkably ERα mediated bioactivity, unlike ERβ, did not correlate 
with lung cancer outcome in our dataset. This was surprising as ERα mediated 
bioactivity was moderately correlated with ERβ mediated bioactivity with a 
Pearson’s correlation coefficient of 0.4888 (p<0.0001). Immunochemistry 
studies in cell lines and in patient samples were unable to detect full-length 
ERα either in normal lung (in the bronchial epithelium and fibroblasts) and 
lung tumor extracts (Stabile et al. 2011). The presence of presumably non-
functional NH2-terminal truncated variants of ERα found in the cytoplasm of 
lung cancer cells can be inferred by the absence of ERα expression using 
antibodies raised against the NH2-terminus of ERα (Raso et al. 2009). 
Although a Japanese study concluded that high ERα expression in NSCLC 
patients was associated with poorer outcome (Kawai et al. 2005), our finding 
that ERα mediated bioactivity in sera does not relate to survival is consistent 
with studies indicating that the expression of the truncated receptor itself was 
not predictive of survival (Stabile et al. 2011). 
 A key strength in our study is the ability to study the effect of 
estrogenic biomarkers on survival in a homogeneous population in relation to 
ethnicity and gender. A potential limitation in our study was that a proportion 
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of the blood samples was not immediately obtained from lung cancer patients 
after diagnosis and that some of them may have received chemotherapy.  
However, the lag time between diagnosis and blood collection was adjusted 
for in our multivariate models. Patients are unlikely to receive chemotherapy 
within 2 weeks of diagnosis. Our sample size may be too small for adequate 
subset analysis and there is a possibility that the positive finding on ERβ 
activity was due to chance (type I error; false positive) because multiple 
comparisons with 8 biomarkers were made. Many of these patients may have 
passed away from non-lung cancer related causes, including causes that are 
also related to estrogenic factors such as coronary heart disease, breast cancer 
and complications from hip fracture.  
Although many in vitro and cell-based approaches that impact ER signaling 
are available, we chose a HeLa-cell based transcriptional assay as it is robust 
and reproducible (Li et al. 2009; Wong et al. 2007b). A limitation of this assay 
is that ER-mediated effects may be exerted indirectly downstream of ER 
ligand binding. However post-receptor effects would involve both ERα and 
ERβ bioassays equally, arguing against this reason for the ERβ selective 
effects observed in our study.  
 In summary, high levels of ERβ-mediated bioactivity in sera were 
associated with worse prognosis in Chinese postmenopausal lung cancer 
patients independent of estradiol levels. Although the many factors contribute 
to lung cancer survival, this is the first study to our knowledge, which 
implicates serum activators of ERβ in the progression of late-stage lung cancer 
in postmenopausal women. If confirmed, our findings suggest that the 
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measurement of ERβ bioactivity could potentially serve as a prognostic factor 
for predicting response in the treatment of lung cancer. The development of 
ERβ specific antagonists to treat lung cancer patients should be investigated 
further as to its use to identify patients who may respond to anti-estrogen 
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Chapter 5: Conclusion and Future Work 
 
The studies presented in this thesis clearly show that measurement of 
both estrogens and ERα/ERβ receptors mediated bioactivity allows for the 
prediction of the risk of diseases such as hip fractures and breast cancer in 
postmenopausal women. In addition, it can also be utilized to predict the 
survival rates in lung cancer patients. In all three studies, correlation between 
free estradiol levels and estrogen receptor mediated bioactivity is weak, 
indicating that these two parameters are indeed distinct and independent 
measures of estrogenic activity. Thus the measurement of estrogen receptor 
bioactivity in addition to estradiol levels will provide better estimation of risk 
in these diseases in postmenopausal women. More research is warranted to 
identify estrogenic compounds present endogenously in the blood, or derived 
from the diet or environment that could activate estrogen receptors and 
influence the risk/survival of these diseases. 
The results obtained also indicated that there are indeed differences in 
the role of estrogenic biomarkers in the risk of hip fracture and breast cancer 
between Caucasian and Asian women. For hip fracture, estradiol was 
associated with hip fracture risk in postmenopausal Asian women. However, 
recent studies done on Caucasian postmenopausal women reported no 
independent association of estradiol with hip fracture risk (Chapurlat et al. 
2000a; Lee et al. 2008b). As for breast cancer, only estrone and not estradiol 
was associated with breast cancer risk in postmenopausal Asian women. 
Conversely, high estradiol was found to be an independent predictor of higher 
breast cancer risk in postmenopausal Caucasian women(Key et al. 2002b). 
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These differences are discussed in the previous chapters and are mainly due to 
differences in anthropometric, environmental and lifestyle factors between 
Caucasian and Asian postmenopausal women. 
As the correlation between free estradiol levels and estrogen receptor 
mediated bioactivity is weak in all our above studies, the association between 
these two biomarkers and disease risk and survival differs. For hip fracture, 
both free estradiol and ERα mediated bioactivity predicts the risk of disease 
independently of each other. Thus, both estradiol and ERα mediated 
bioactivity act through different mechanisms to protect against risk of hip 
fracture. For breast cancer, both estrone and ERα mediated bioactivity predicts 
the risk, however after additional adjustment of each other only estrogen 
receptor α mediated bioactivity remain significantly associated with breast 
cancer. This indicates that estrogens influence breast cancer risk through ERα 
activation. In terms of lung cancer survival, only ERβ and not ERα mediated 
bioactivity was associated with worse prognosis, suggesting that it is a better 
biomarker for survival prediction as compared to estradiol levels in our cohort.  
For hip fracture, only free estradiol and not estrone was associated 
with reduced risk. Levels of estrone are about three times higher than estradiol 
in postmenopausal women due to its production in several tissues especially in 
the adipose tissues. In all three studies, only estrone levels were significantly 
associated with breast cancer risk. This may be because although estrone is 
more abundant, estradiol is about ten times more potent. Despite this, estrone 
also binds to estrogen receptor (Bhavnani, et al. 2008) and contributes to the 
bioactivity in the bioassay. In the case of breast cancer, estrone as compared to 
estradiol may have different mechanisms to promote disease progression. 
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 The measurement of SHBG allows for the calculation of free estradiol, 
which provides a more sensitive prediction of risk. Only free estradiol in the 
blood can freely enter target cells and activate estrogen signaling. Interestingly, 
SHBG did not show an independent risk prediction in all three studies. In 
studies done on Caucasian women, SHBG was shown to be an independent 
predictor of the risk of breast cancer and hip fracture (Key et al. 2002b). 
InKey et al. 2002b). In addition to binding to sex steroids and limiting it’s 
bioavailability to target cells, SHBG could act as an independent mediator of 
multiple signaling pathways in sex hormone responsive cells. For example, 
sex hormone-bound SHBG may bind its own cell membrane receptor 
(Fortunati and Catalano 2006; Kahn, et al. 2002) and steroid-free SHBG may 
bind to an endocytic receptor (Hammes, et al. 2005) to mediate intracellular 
sex hormone signaling and cell function. For hip fracture, SHBG itself might 
directly influence bone mineral density (BMD) and certain mutations in the 
SHBG gene are found to be associated with circulating SHBG levels and 
BMD (Eriksson, et al. 2006). The lack of independent association between 
SHBG and hip fracture or breast cancer risk may be due to lower body mass 
index (BMI) of Asian postmenopausal women. Lower BMI is associated with 
higher SHBG levels (Maggio, et al. 2008a) and the excess SHBG present in 
Asian women may have attenuated the association between SHBG and risk of 
breast cancer or hip fracture. 
In all three studies, levels of genistein and daidzein were not associated 
with the risk of hip fracture and breast cancer and survival of lung cancer. 
Although genistein levels were shown to be able to predict risk of breast 
cancer (Iwasaki, et al. 2008a; Verheus, et al. 2007a), we were not able to show 
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that in our current study.  Possible reasons would be the lack of numbers and 
that blood specimens were not collected after overnight fasting; these levels of 
genistein and daidzein may not be representative of the individuals diet 
patterns and therefore are not good biomarkers to predict risk or survival. In 
this situation, the food frequency questionnaire would be a more accurate 
representative of the individual soy food intake patterns. 
A common limitation of the above studies is that the disease 
risk/survival prediction is based on a single blood measurement of hormones 
and estrogenic activity. Despite this, it was shown that estrogen levels 
measured 16-20 years before breast cancer diagnosis has the ability to predict 
postmenopausal breast cancer risk (Zhang, et al. 2013). Furthermore, a study 
was conducted to investigate the reproducibility of hormones within a 2 to 3 
year period showed high correlation between time periods with an intraclass 
correlation coefficient of at least 0.7 (Hankinson, et al. 1995b). This indicates 
that the levels of estrogens in postmenopausal women were highly correlated 
between different time periods and that a single measurement was sufficient 
for disease risk prediction. 
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Future work 
  
Estrogen levels decline steadily at a rate of 35% reduction from age 
35-50 in women (Figure 5.1). However, the risk of hip fracture only starts 
increasing when a woman reaches the age of 50 (Figure 5.2). This supports 
findings from our hip fracture study (Chapter 2) where higher estrogen levels 
and ERα mediated bioactivity in postmenopausal women are protective 
against hip fractures, as summarized above. 
Despite this, it is also important to note that estrogens exert its effects 
on many other organ systems (Figure 1.1) and higher levels may have adverse 
effects. This was evidenced by the use of estrogen replacement therapy for 
alleviation of postmenopausal symptoms was found to increase the risk of 
coronary heart disease, stroke, breast cancer and pulmonary embolism in the 
Women’s Health Initiative (WHI) study (Rossouw, et al. 2002). Therefore, 
currently there are strict guidelines to guide judicious and cautious use of 
estrogen replacement therapy in non-contraindicated women for short-term 
relief of postmenopausal symptoms only (2014 ; Panay, et al. 2013).  
This is further validated by our breast cancer study (Chapter 3) where 
we demonstrated that high ERα mediated bioactivity increases the risk of 
breast cancer in postmenopausal women. Therefore there arises a clinically 
important and relevant question of where a threshold level of estrogenic 
activity may lie between protection against hip fracture and risk of breast 
cancer. This optimal window of ER bioactivity (Figure 5.3) can guide 
clinicians to achieve a target of protecting against hip fracture while not 
increasing the risk of breast cancer.  
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To determine the threshold estrogenic bioactivity levels, we propose 
combining data from both case-control studies, including both hip fracture and 
breast cancer cases and their corresponding controls. This may be achievable 
using “an inverse probability weighted concept, in which the log-likelihood 
contribution of each individual observation is weighted by the inverse of its 
probability of inclusion in either study”, which has been successfully 
demonstrated using 2 nested case-control studies with overlapping cohorts 
(Salim, et al. 2009). 
The presence of this optimal window will have the potential to change 
the management of postmenopausal women patients by providing clinicians 
with a more informed decision of prescribing hormone replacement therapy to 
women only when levels of estrogenic biomarkers measured are below the 
threshold level that protects against the risk of hip fracture. 
 
 
Figure 5.1: Estrogen levels throughout the lifetime of a woman. 
	  
 








Figure 5.2: Estimated incidence of fracture as a function of age and bone 
mass in women. 	  
	  
Data are from a follow-up of 521 Caucasian women over an average of 6.5 
year with repeated bone mass measurements at the radius. A total of 138 non 
spinal fractures in 3388 person-years were detected, and the incident fractures 
were cross classified 
by age and bone mass. The incidence of fracture was then fitted to a log-linear 
model in age and bone mass. [From S. L. Hui et al.: J Clin Invest 81:1804–
1809, 1988 (Hui, et al. 1988a). Reproduced with permission from The 











Figure 5.3: Optimal window of estrogenic activity for low fracture risk 




In addition, the development of estrogen receptor bioassay as a clinical 
tool to predict the serum estrogenicity of postmenopausal women will allow 
clinicians better manage patients with risk factors of breast cancer and hip 
fractures. For example, if the levels of estrogenic activity fall below a certain 
level clinicians can recommend more frequent screening tests for bone mineral 
density or consumption of more soy product to prevent osteoporosis. On the 
contrary, if levels of estrogenic activity are too high, clinicians can 
recommend yearly instead of biannually screening tests for breast cancer in 
postmenopausal women.  Factors to consider for the development of estrogen 
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receptor bioassay as a clinical tool include standardization of calibration 
standards, reproducibility of bioassay over a prolonged period and additional 
cost to patients including consumables and technical expertise. 
 
Subsequently it would be important to determine whether the 
measurement of estrogen receptor mediated bioactivity could increase the 
sensitivity and specificity of current disease risk prediction tools, such as the 
FRAX score for hip fracture (Melton, et al. 2012). If the discriminating ability 
and area under curve of the “FRAX + ER bioactivity” tool improves, it would 
make for a strong case to incorporate this into clinical practice. Additionally, it 
will be useful to determine the value of measuring estradiol levels and whether 
it may improve risk prediction of postmenopausal breast cancer. 
Further work includes the development of other nuclear receptor 
bioassays such as androgen receptor bioassay to measure the androgen 
receptor mediated bioactivity of the serum. This could potentially be used to 
predict risk of other diseases in male such as prostate cancer or in women 
where androgens may have a role to play in the risk or progression of diseases 
such as polycystic ovarian syndrome or even breast cancer and hip fracture.  
From the literature, androgen receptor bioassays have been developed to 
measure androgen bioactivity of human serum but none have been used for 
specific disease risk prediction (Paris, et al. 2002b; Raivio, et al. 2001; Raivio, 
et al. 2002; Roy, et al. 2006). 
In addition, future work would be to look at the association between 
estrogenic factors and risk of lung cancer in a case control study based on a 
prospective cohort where blood was collected pre-diagnosis. The blood 
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sample from our lung cancer study is based on a case control study and 
therefore blood was taken after cancer diagnosis. It would not have been 
appropriate to look at the risk in this case control study as most patients were 
in stage four of lung cancer thus the role of estrogens in predicting the risk of 
lung cancer would not be accurately represented. Blood collected pre-
diagnosis will be more relevant for risk prediction of lung cancer in 
postmenopausal women and the issue of reverse causation can be avoided. 
Furthermore, it would be interesting to look at the association between 
reproductive factors with estradiol levels and ER bioactivity in 
postmenopausal women base on all the controls investigated in these three 
studies. Previous studies have only examined the association between 
reproductive factors and estradiol levels in postmenopausal Caucasian women 
(Hankinson et al. 1995a; Key et al. 2011; Madigan et al. 1998). It would be 
interesting to look at whether the association between ER bioactivity and 
reproductive factors would be different from estradiol levels or even different 
in Asian postmenopausal women. This will provide further information on 
how reproductive factors influence risk of diseases in postmenopausal women. 
To further extend our research, we can investigate the role of 
estrogenic biomarkers especially estrogen receptor mediated bioactivity in 
other diseases that have been well associated with estrogens or reproductive 
factors in postmenopausal women. These include non-communicable diseases 
such as cardiovascular disease (Scarabin-Carré, et al. 2012), hypertension 
(Wang, et al. 2012), stroke (Lee, et al. 2010) and colorectal cancer (Lin, et al. 
2013).  The results obtained could potentially provide insights to the 
mechanism of disease initiation or progression in postmenopausal women. 
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